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 ABSTRACT 
 
 
This thesis summarises the progress made in the design and synthesis of 
conformationally constrained β-strand peptidomimetic compounds using ring closing 
metathesis methodology under microwave irridation conditions.  The best macrocycle 
were elaborated into an inhibitor for a specific protease target. Calpain was used as an 
example of protease targeting cataract disease. 
 
Chapter One introduces proteases in general centring on the general context of 
protease inhibitor design. The significant of the β-strand ‘bioactive’ conformation is 
discussed in details in particular the exploitation of conformationally constrained to 
potential lock the ‘bioactive’ conformation.  
 
Chapter Two illustrates in silico methods used to design a series of β-strand 
macrocycle 2.1-2.7. The analysis of these is performed using molecular modelling 
software Schrodinger suite (2005). A brief discussion of ring closing metathesis 
methodology is also included. 
 
Chapter Three describes the synthesis of the precursor required for RCM reactions 
(tripeptides dienes). Various types of allylated amino acid side chains were 
synthesised. The tripeptides were obtained using standard peptide coupling 
methodology utilising reagents such as HATU, EDC and HOAT.  
 
Chapter Four describes the application of ring closing metathesis for the synthesis of 
β-strand macrocycles. The development of a new reaction conditions to optimise the 
ring closing metathesis reaction is discussed. In particular the effect of the use of a 
Lewis acid (chlorodicyclohexylborane) additive in RCM reactions is investigated. 
 
Chapter Five discusses the mechanism of cataract formation, cataract treatment and 
the potential development of calpain inhibitors.  One of the macrocycles synthesised 
in chapter 4 is elaborated into a calpain inhibitor. The in-vitro assay result of this is 
presented and this compound is currently undergoing in vivo evaluation.  
 ABBREVIATIONS 
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1.1 PROTEASES 
 
Proteases were initially recognized as gastric juice proteolytic enzymes that catalyse 
the non-specific degradation of dietary proteins.1 These enzymes are now known to be 
central to many fundamental processes which determine protein synthesis, 
compositions, shape and size. Thus proteases are implicated in most physiological 
processes including cell signalling, migration and activation, fertilization, 
transcription, blood coagulation, morphogenesis and apoptosis. Deregulation of these 
proteolytic enzymes can disturb the balance of proteolytic activities and hence have 
been shown to engender several diseases; cataract2,3, cancer4,5, rheumatoid arthritis6, 
bacterial and viral infections such as pneumonia7, HIV8,9 and neurological diseases 
such as Alzheimer’s10. Consequently the ability to control protease expressions and 
functions is an ideal therapeutic target.  
 
Approximately 2% of human genes encode proteolytic enzymes.11 This large group of 
enzymes consists of six sub-classes which are classified according to the nature of 
their active site: metallo protease e.g. angiotensin-converting enzyme (ACE), serine 
e.g. thrombin, cysteine e.g. calpain, aspartic e.g. HIV-1 protease, threonine proteases 
e.g. threonine 20S proteasome and glutamic proteases.12 These proteases catalyse 
sequences of the amide bond using nucleophiles; direct amide hydrolysis by water 
molecule (metallo and aspartic proteases) or an enzyme activated nucleophile (a 
nucleophilic atom from the amino acid residues) to attack the amide carbonyl atom. 
The thiol group of cysteine and the hydroxyl group of serine and threonine residues 
belong to the latter class Scheme 1A.  
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Scheme 1A: The catalytic triad of cysteine  
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Most proteases are sequence-specific with respect to their characters for instance; 
hydrophobicity/hydrophilicity and the size of enzyme sites dictate the possibility of 
binding between the enzyme-substrate/inhibitor.13 This complementary binding 
characteristic of the enzyme-substrate/inhibitor is designated using the standard 
nomenclature; P3, P2, P1, P1΄, P2΄, P3΄. This nomenclature is used to designate amino 
acid residues of substrate/inhibitors that bind to the corresponding sub-site of enzyme 
S3, S2, S1, S1΄, S2΄, S3΄. The scissile peptide bond is P1-P1΄ Figure 1A14.  
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Figure 1A14: The standard nomenclature for substrate residues and their 
complementary enzyme binding sites 14 
 
Over the past decade protease drugs such as Captopril and Crixivan have shown some 
promising therapeutic uses towards the inhibition of angiotensin converting enzyme 
and HIV proteases, respectively.13 These protease drugs have been successfully 
approved by the Food and Drug Administration and are commercially available.  The 
success of protease drugs along with the fact that proteases play a vital part in disease 
propagation have opened up a wide-ranging field in the design of protease inhibitors.  
 
Unfortunately designing such inhibitors is not an easy task with enormous amounts of 
work from the preliminary stage until the finish line. The traditional approach to 
protease inhibitors is to mass screen libraries of natural/synthetic products for lead 
compounds. This allows the establishment of structure-activity relationships (SAR) 
that contain a significant amount of information useful in designing protease 
inhibitors. However, over the past decade advances in molecular biology and protein 
chemistry together with advances in analytical methods such as nuclear magnetic 
resonance (NMR), X-ray crystallography and computer modelling programs has  
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allowed the elucidation of three-dimensional structures of proteases. These 
technologies have opened up the field of designing protease inhibitors by proving 
details on their active sites.8 Once an active site has been identified a large selection 
of molecules can dock and interactions between enzyme-substrate/inhibitors can be 
investigated8 in silico. A combination of these powerful techniques aids in the 
synthesis of protease inhibitors. 
 
 
1.2 CALPAIN PROTEASE 
 
Calpains were first isolated in 1964 (from the rat brain)15 and were subsequently 
defined as an intracellular enzyme belonging to the cysteine protease class family. 
The name “calpain” was introduced in 1981 where ‘cal’ refers to the Ca2+ activation 
enzymes and ‘pain’ refers to the analogy between the cysteine proteases with 
papain.16 The universal forms of calpains are µ-calpain and m-calpains (calpain I and 
II). These terms µ and m were first used in 1989 to describe the micro and millimolar 
concentration of Ca2+ required for proteases, respectively.17 Calpains occur with their 
endogenous inhibitors ‘calpastatins’ section 1.3.1 in almost all vertebrate cells, fungi, 
Drosophila and Schistosoma mansoni and as transmembrane protein in plants.17 
 
1.2.1 Structure  
 
Crystallographic structural information of calpains has become available over the last 
10 years with µ and m calpains (calpain I and calpain II) being the most prominent 
isoforms characterized. The crystal structure solved for both expressed full length 
human and truncated rat m-calpain, in an absence of calcium binding, have shown 
them to be identical.15 The two forms of calpain (I and II) are heterodimers consisting 
of large (80kDa) and small (30kDa) subunits. The large and small subunits are 
comprised of domains I-IV and domains V-VI respectively. The two sub units are 
occupied by the two catalytic sub-domains which are opposed to each other: Domain 
II consists of sub domains IIa(gold) and IIb(red) representing the catalytic triad Cys  
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105, His 262, Asn 286. Domain IV (yellow) and domain VI (orange) represent the 
calcium binding site ‘calmodulin’ like Figure 1B.18 
 
 
 
Figure 1B18: Crystallographic structure of Ca2+-free human m-calpain (calpain II) 
 
Domain I (green) is an NH2–terminal sequence consisting of short amino acids 
‘anchoring helix’ embedded in a surface cavity of domain VI. It has been suggested 
that the interaction between dI and dVI stabilizes the catalytic triad in an inactive 
state.19  
 
Domain II is the protease domain. As previously stated this domain represents the 
catalytic triad (Cys, His, Asn) characteristic of cysteine proteases such as papain and 
cathapsins. Cysteine 105 is situated in sub domain IIa (C105 grey) whereas His and 
Asn (grey) are situated in sub domain IIb.18 
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Domain III (blue) is the central domain consisting of two antiparallel β-sheets. This is 
a C2-like domain that may possibly be involved in binding to phospholipids. The side 
chains of domain III consist of the solvent-exposed negatively charged acidic loop 
(blue). These acidic loops interact electrostatically to a positively charged basic loop 
on domain IIb. This electrostatic interaction is believed to have a significant role in 
calcium regulation of the calpain activity. 20  
 
Domain IV (yellow) is like domain VI (orange), these domains have sequence 
homology to calmodulin. The two domains have five EF-hand sequences which are 
involved in dimerisation of the large and small sub-units forming a heterodimer. The 
crystallographic evidence and the evidence from limited proteolysis illustrate that 
Ca2+ binding to the penta-EF hand domains caused a small conformational change to 
the overall calpain structures.17 
 
Domain V: The crystal structure does not clearly indicate domain V. This domain is 
believed to contain the hydrophobic region; an N terminus glycine that is essential for 
calpain interaction with membrane which may be involved in modulation towards the 
calpain activity.21 
 
1.2.2 Activation  
 
The crystal structure of Ca2+ free human m-calpain (calpain II) Figure 1B18 illustrates 
the active site of calpain in its inactive form (dII) and the calcium binding site (dIV 
and dVI). Nonetheless the mechanism of calpain is yet to be elucidated and much 
effort has gone into attempts to generate such mechanism. However these efforts have 
proven to be unsuccessful given that calpains are susceptible to autoproteolysis.22,23 
Recently Moldoveanu et al. successfully constructed recombinant mini-calpains (µ-
calpain and m-calpain) comprising the catalytic domain II.24 The catalytic triad is 
arranged in both active (Figure 1C Left) and non active conformations (Figure 1C 
Right).25  
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Figure 1C: Left) Crystal structure of calcium free state calpain with a significantly 
separated between the catalytic residues Cys 105 and His 262 by 10 Ao. Right) 
Crystal structure of calcium bound calpain with the catalytic residues in close 
proximity of 3 Ao. 
 
The activation of Calpains is triggered by increasing the intracellular concentration of 
Ca2+ which is controlled by the endogenous inhibitor calpastatin (section 1.3.1). The 
amount of in vitro calcium required for the two isoforms of calpains is 5-50µM for the 
µ-calpain and 200-1000µM for the m-calpain.23 The differences in requirements of 
Ca2+ are presumably due to the diversity in the acidic loop of domain dIII (an 
electrostatic switch) within the isoforms of calpains.23 The acidic loop of m-Calpains 
consists of larger acidic residues compared to the other isoforms of calpains.26 Thus 
creating a stronger charge repulsion between the calcium ions and these loops. Hence 
higher concentration of calcium ions in m-calpain is required to compensate these 
electrostatics interactions.26, 20 
 
The calpain activation in vivo requires a much lower concentration (1µM at most) of 
calcium ions compared to in vitro to facilitate the activation of µ/m calpain. The 
variation in calcium sensitivity is likely due to other possible biological molecules 
such as protease inhibitors and phospholipids.23,26 Nevertheless this issue still remains 
unclear and is yet to be resolved. 
  
10 Å 
3 Å 
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1.2.3 Function 
 
Calpains participate in a number of cellular processes including; cytoskeletal 
attachments to the plasma membrane such as cell fusion of skeleton muscle myoblast 
and cell motility, signal transduction such as the kinases and phosphatases, 
degradation of enzymes required towards the progression through the cell cycle 
mitosis/meiosis, regulation of gene expression by cleavage of several transcription 
factors such as p53 and program cell death which is known as ‘apoptosis’.17 
 
Several calpains homologous have been reported in invertebrates.27,28 A calpain 
homologous in nematodes C. elegans Tra-3 is involved in the sex determination 
cascade during early development.15,28 Recently two of the human calpain 
homologous database entries Y10552 and AJ000388 have been found to be 
complementary to the mouse Y10656 and Y12582 entries, showing significant amino 
acid resemblance to Tra-3a.15 AJ000388 (human) and Y12582 (mouse) which are 
localised at X-chromosomes in both species.17,29 Consequently it is possible that 
calpain may  be involved in sex-determination cascade in mammals.15 
 
The over activation of calpains resulting from genetic or elevated levels of Ca2+ has 
also been implicated in pathological systems. Diseases such as Limb Gridle Muscular 
Dystrophy type 2A (LGMD2A), type II diabetes, mellitus and gastric cancer are 
caused by disruption in the gene Capn3a (p94), Capn10 and Capn9 (nCL4) 
respectively.30, 31, 32 
 
Disruption of calpain function via genetic or the elevated level of Ca2+ is known to 
engender various pathological diseases such as; neurological injuries, Alzheimer’s 
disease (AD) and Cataracts (Chapter 5).17 The study of traumatic brain injuries and 
ischemia have illustrated the involvement of calpain activations15,27 where the 
relationship between calpain and ischemia is well documented.33, 34, 35 In the case of 
AD, it is believed that aggregations of β-amyloid peptide together with the build up of 
glutamate causes the over activation in the amount of Ca2+ levels which leads to the 
formation of AD.27,36 Finally regarding cataract formations, it has become  
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increasingly clear that the over activation of calpain results in the proteolysis of the 
crystallins protein inducing opacification in the lens.2 (section 5.1) 
 
 
1.3 CALPAIN INHIBITORS 
 
 
Over the past 30 years a large number of calpain inhibitors have been identified from 
both natural products and chemical synthesis.37,38 Unfortunately most of these 
inhibitors have poor metabolic stability, low cell penetration and poor selectivity.39 To 
overcome these issues the inhibitors must be modified in order to maximise their 
pharmaceutical potential.  
 
1.3.1 Naturally Occurring Calpain Inhibitors 
 
The most potent of all calpain inhibitors is the endogenous polypeptide ‘Calpastatin’. 
Calpastatin is 120 kDa protein consisting of four repetitive inhibitory domains (A-D)  
which bind preferentially to separate domains of calpain.40 Domains A and C interact 
with calpain domains IV and VI respectively in a Ca2+ dependent manner.31 While 
domain B appears to inhibit calpains by binding at or near the catalytic active site 
(domain II).40 Thus calpastatin selectively inhibits both of the isoforms µ-calpain and  
m-calpain without inhibiting other groups of cysteine proteases such as Papain and 
Cathepsin B. 41,17,42  
 
Leupeptin 1.1 is a peptidyl aldehyde class inhibitor isolated from Streptomyces 38. It 
deactivates calpains by reversible bind to the thiol group of the active site cysteine 
residue of the catalytic triad. 38,42 
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The peptidyl aldehyde class of inhibitors including Leupeptin have low selectivity 
towards the calpain as these inhibitors also inhibit other classes of cysteine protease 
such as cathepsin B and papain.38 Furthermore, the peptidyl aldehyde inhibitors 
exhibit low cellular permeability, for example in the case of Leupeptin; the presence 
of the positively charged arginine residue is believed to be the factor that creates the 
poor cellular permeability.43 Consequently this class of inhibitors is limited in its 
therapeutic potential. 
 
E-64 1.243 belongs to the peptidyl epoxysuccinate class of irreversible inhibitors that 
are isolated from Aspergillus japonicus 44. This inhibitor covalently binds to the active 
site cysteine of the calpain forming an irreversible sulphide linkage.  
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1.3.2 Chemical Synthetics Calpain Inhibitors 
 
Simple calpain inhibitors consist of a dipeptide that interacts with S1 and S2 
recognition sites, an aromatic capping group in the S3 recognition site, and an 
electrophilic warhead that can either reversibly or irreversibly bind to the active site 
cysteine23 (P1scissile bond) See Figure 1A14. 
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Examples of reversible inhibitors include; aldehydes45 (1.3 IC50 7.5 nM), α-keto 
carbonyl compounds such as α-ketoamides46 (1.4 IC50 190 µM ), α-ketoacids, and α-
ketoesters.47 These inhibitors contain an electrophilic warhead that forms a tetrahedral 
transition state intermediate during the substrate hydrolysis.38  
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Examples of irreversible inhibitors include fluoromethylketones48 (1.5 IC50 0.1 µM 
Calpain I) and peptidyl epoxides38 (E-64 analouges) 1.2. 
 
P
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O Ph
O
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Compounds of the type 1.3-1.5 are typical of the vast majority of published calpain 
inhibitors. As illustrated by the generic structure 1.6, these consist of a dipeptide back 
bone which must be able to adopt a β-strand conformation when bound into the 
enzyme active site. An additional recognition group and warhead are used to confer 
calpain inhibitory activity. 
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Dipeptides are flexible molecule which exist in various conformations, however only 
one of these conformation is responsible for its biological activity.  The majority of 
known protease inhibitors are conformationally flexible13,49,50,51 and have a low 
affinity to bind with protease. This is because the inhibitor must first spend time and 
energy to arrange itself into the ‘bioactive’ conformation to enable protease 
recognition.52 As shown in Figure 1D52  the maximum inhibition is dependent on the 
conformation selection. The random inhibitor (Iiact) must first form pre-equilibrium 
with the selected conformation (Iact) before the enzyme binding take places. Therefore 
if the inhibitor are preorganised into the desired ‘bioactive’ conformation the entropy 
loss during this pre-equilibrium stage can be minimise thus facilitating the enzyme-
inhibitor binding. 
 
Iinact Iact E.I
E
Helix
Turn
kx
k
-x
k
-1
k1
 
 
Figure1D52. Conformational equilibria and the proposed conformational selection of 
protease-inhibitor complex. Where Iinact/Iact = Inhibitor in an inactive/active 
conformation respectively. 
 
In peptidomimetic research a key design approach is to mimic this ‘bioactive’ 
conformation by incorporating additional structural features to stabilise the desired 
conformation. This thesis describes such approach. Chapter 2 and Chapter 5 detail 
the design and synthesis of novel conformationally constrained macrocyclic calpain 
inhibitors.  
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1.4 β-Strand ‘Bioactive’ CONFORMATION 
 
Proteases have a propensity to recognise/bind polypeptide substrate via their bioactive 
surfaces. However once poly peptides substrate have been removed from the protease 
they rapidly changes their conformations in solution into random structure.53 Theses 
random structures have a tendency to fold via intramolecular hydrogen bonds52, 
forming a thermodynamically stable secondary structure including α helix, β-strand, 
β-sheet and β and γ turn.  
 
Fairlie et al. have analysed over 1500 three dimensional protease crystal structures 
deposited in the Protein Data Bank54 to identify the required conformation of protease 
classes. From this it was concluded that proteases universally bind their 
substrate/inhibitor in an extended β-strand conformation (Figure 1E12).  
         
 
Figure1E12: An overlay of the backbone of known inhibitors bound to the proteases 
in the extended β-strand conformation. Left) substrate bound structure to mutant 
Feline immunodeficiency virus (FIV) retropepsin (aspartic protease). Right) protease-
inhibitor bound structure of Trombin cyclic inhibitor PPACK (D-Phe-Pro-Arg-
Chloromethyl ketone) (serine protease). 
 
The β-strand motif consists of a short peptide sequence (<10 residue) that exists as an 
extended ‘saw tooth’ arrangement of amino acids with their side chains alternating 
anti-parallel to one another and the amide bonds orthogonal to the side chains (Figure 
1F a)). The torsion angle of β-strand structure; phi (φ), psi(ψ), omega (ω) have 
optimum angles of – 120o, 120o and 180o respectively. (Figure 1F b)) 
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Figure 1F: a) A three dimensional β-strand conformation54 b) Another view of the 
extended β-strand with torsional angle. 
 
Adoption of this extended β-strand conformation means that there is a great 
separation between the adjacent amide bonds thus preventing intramolecular 
hydrogen bonding. At the same time this conformation also allows the side chain 
residues to have maximum exposure to the protease’s active sites which in turn 
facilitates protease binding.55   
 
The discovery that proteases bind their substrate/inhibitors universally in a ‘β-strand’ 
conformation has laid the foundation for the development of a new and general class 
of protease inhibitors. To be an effective protease inhibitor a molecule must adopt the 
β-strand ‘bioactive’ conformation before binding to the enzyme active site.  
 
1.4.2 Conformationally Constrained Protease Inhibitors 
 
Macrocyclisation is one possible approach for conformationally constraining an 
inhibitor into the β-strand ‘bioactive’ conformation. Furthermore this confers a 
significant entropy advantage.56,57 In addition macrocyclisation is also expected to 
increase the metabolic stability and the bioavailability. Thus macrocyclic inhibitors  
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should exhibit more promising pharmacological properties in comparison to their 
acyclic analouges.49,56,57 
 
The use of macrocyclisation also counteracts the cooperative nature of the enzyme 
inhibitor binding. If changes are made in a linear peptide inhibitor this will also 
induce changes in the local enzyme environment, which in turn influences the 
enzyme-inhibitor interactions at adjacent locations.57 This process is commonly refer 
to as ‘the induce fit’.58 However macrocyclic inhibitors bind in a precise manner such 
that these do not induce changes in the local enzyme environment.  
 
There are various ways to create macrocyclic peptidomimetic compounds; side chain 
to N-terminus cyclisation 1.759, side-chain to side chain cyclisation 1.859 and N to C 
cyclisation 1.9.52 Such conformationally constrained protease inhibitors have already 
been shown to be potential therapeutic agents.12  
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1.5 WORK DESCRIBED IN THIS THESIS 
 
This thesis focuses on the design and synthesis of β-strand conformationally 
constrained compounds formed via side chain-side chain linkages. A virtual library of 
potential β-strand mimics was prepared with in the group by Steven Aitken. 
 
This library contained a total of 272 potential macrocyclic β-strand mimics. All these 
underwent conformational analysis in silico to determine the Boltzmann weighted 
percentage β-strand conformation with in the conformational distribution (Chapter 
2). The best ones of these macrocycles were selected for synthesis. 
 
The synthesis was divided into 2 parts. Firstly tripeptide dienes were synthesise 
(Chapter 3). Next ring closing metathesis (RCM) was employed with Grubbs second 
generation catalyst (2.12) under microwave conditions (1200W) to cyclise the dienes 
to form the desired macrocycles (Chapter 4).  The last part of this thesis describes 
elaboration of these macrocycles into calpain inhibitors (Chapter 5). 
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2.1 DESIGNING β-STRAND INHIBITORS  
 
 
A library of 272 (17 x 16) possible novel β-strand macrocyclic inhibitors consisting of 
14-22 membered macrocyclic rings were created by Steven Aitken1.  All macrocycles 
consist of a tripeptide backbone. The selected macrocycles 2.1-2.7 were studied in-
silico within our group by Blair Stuart, Axel Neffe and Steve Aitken. All molecular 
modelling experiments were conducted with the Schrodinger suite 2005.  The 
macrocyclic compounds were subjected to conformational searches using 
Macromodel 9.0 to find both the lowest energy conformer and to create an ensemble 
of the low energy conformations which were within a 12kJ window of the global 
minimum.  The conformational searches were conducted with MCMM method and 
were run with a GB/SA water model, using the OPLS2001 force field, with 1000 
steps for the conformational search and up to 500 iterations for the minimization of 
each generated structure. The minimization was performed with the default gradient 
convergence threshold of δ = 0.05 kJ/(mol*Å). For all minimizations, the default 
Polak-Ribiere Conjugate Gradient method was used.2 
 
The structures within the 12 kJ/mol window were analysed further (using a computer 
program written by Blair Stuart2) to determine whether these macrocycles favour β-
strand conformations. The Boltzmann weighted percentage of β-strand, twist and turn 
for each ensemble were calculated (Note that the turn conformation resemble γ-turn). 
The distance between the hydrogen atom of the amide bond and the oxygen from the 
carbonyl at the P2 position (shown in yellow dash for each macrocycle see Figure 
2.1-2.7) was used to determine whether each individual conformer in the ensemble 
was a β-strand, twist or turn. As illustrated in Figure2A2,3 a calculated distance of less 
than 3.1 Angstroms represented a β-strand and a value greater than 3.7 Angstroms 
represented a turn, intermediate values represented a twist.   
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Figure 2A2,3: Distance between equivalent atoms used to distinguish between Top) β-
strand  (<3.1 Angstroms) and Bottom )β-turn (>3.7), and twist (3.1<twist<3.7). 
 
The Boltzmann weighted percentages of conformers were calculated and these are 
illustrated in the table (Figure 2.1-2.7) below each macrocyclic compound. The 
Boltzmann weighted percentage of each macrocyclic ensemble (compound 2.1-2.7) 
indicates that each is a potential β-strand conformational constraint.  
 
It should be noted that the modelling pictures in this thesis are those representing the 
lowest energy β-strand conformer from each ensemble rather than the global 
minimum.  
 
2.1.1 Tyrosine Based Macrocycles 2.1 and 2.2 
 
The tyrosine based macrocycles are shown in Figure 1 and Figure 2. These 
macrocycles consist of Tyr residues at the P3 positions. Macrocycle 2.1 and 2.2 
contained Glu and Gly residues at the P1 positions respectively.  
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The Boltzmann weight percentages of the two macrocyclic ensemble conformers have 
shown that these tyrosine based macrocycles exhibit an excellent β-strand 
conformation and are two of the best β-strand macrocycle obtained from in silico 
studied in this thesis. 2.1 exhibit 96.84% β-strand and 2.2, 90.01%  
 
As shown in Figure 2.2 the distance between the hydrogen atom of the amide bond 
and the oxygen from the carbonyl at the P2 position is 2.18 Angstroms which clearly 
indicates that macrocycle 2.2 represents a β-strand conformation. Macrocycle 2.2 has 
also been tested for its inhibition potency against calpain. With an IC50 of 45nM 2.2 is 
a very potential calpain inhibitor. (Chapter 5)   
 
Figure 2.1: Tyr-Val-Glu macrocycle 
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Figure 2.2: Tyr-Leu-Gly macrocycle 
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2.1.2 Glutamine based macrocycles 2.3 and 2.4 
 
The 15-membered glutamine based macrocycles consist of Gln at the P3 positions and 
Gly at the P1 position as shown in Figures 2.3 and 2.4. The calculated Boltzmann 
weight percentages of the glutamine based macrocycle shows that the unsaturated 
macrocycle 2.5 exist as 59.57% β-strand conformation and macrocycle 2.4 is 39.23% 
β-strand.   
 
 
 
H
N
N
H
O
O
N CHO
O
S
O
O
F
Compound 2.2 
Chapter 2 - Designing β-strand Inhibitors 
_____________________________________________________________________ 
24 
Figure 2.3: Gln-Val-Gln macrocycle 
 
 
Figure 2.4:Gln-Val-Gly macrocycle 
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2.1.3 Cysteine based Macrocycles 2.5-2.7 
 
The cysteine based macrocycles are shown in Figures 2.5-2.7. These macrocycles are 
all contain cysteine residues at the P1 position while the residue at the P3 position 
varies. The P3 positions of 2.5-2.7 consist of Cys, Ser and Glu residues respectively.  
 
The calculated Boltzmann weighted distribution percentage of β-strand conformation 
is 7.28% for 2.5, 55.1% for 2.6 and 50.57% for 2.7.  The Boltzmann weighted 
percentage of macrocycle 2.5 indicates that the Cys-Cys based macrocycle does not 
favoured the β-strand conformation. In comparison to Ser-Cys 2.6 and Glu-Cys 2.7, 
exhibit over 50% β-strand conformers. This is postulated to be due to the influence 
from the large sulfur atoms which forces the geometry of macrocycle 2.5 away from 
the extended β-strand conformation.  
 
Figure 2.5: Cys-Val-Cys macrocycle 
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Figure 2.6: Ser-Val-Cys macrocycle 
 
 
Figure 2.7: Glu-Val-Cys macrocycle 
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This thesis details the synthesis of the potential β-strand macrocycles 2.1-2.7. The 
syntheses were divided into two chapters Chapter 3 and Chapter 4.  
 
 
2.2 RING CLOSING METATHESIS VIA MICROWAVE CONDITIONS 
 
 
Olefin metathesis was first discovered in the 1950’s following the observation of 
polymerisation during the reactions of the olefins by Ziegler.4 However it was a 
largely unexplored area of chemistry until the early 1990’s and as such it is a 
relatively new reaction for many organic chemists. Therefore the use of the metathesis 
reaction has not been extensively investigated in many areas of organic chemistry. 
Nevertheless in the past decade a tremendous amount of progress has been made in 
the use of olefin metathesis in organic synthesis. 
 
The etymology of the word metathesis shows that it is derived from Greek language 
meaning transposition.5 Currently we understand the term metathesis to mean the 
metal-catalysed redistribution of carbon-carbon double bonds. 
 
There are various classes of metathesis reactions such as ring-opening metathesis, ring 
closing metathesis, ring opening metathesis polymerization (ROM), acyclic diene 
metathesis polymerization (ADMP), eyene metathesis and cross metathesis (CM). 
However ring closing metathesis has emerged as the most prevalent type and it is a 
useful reaction for constructing different sizes of macrocyclic ring systems.5,6 
 
2.2.1 Ring closing metathesis (RCM) 
 
The mechanism of RCM has been studied over a number of years but in 1971 
Chauvin proposed the general mechanism that is still commonly accepted. This 
mechanism consists of a sequence of formal [2+2] cycloadditions to give the key 
intermediate ‘metallocyclobutane’. The metallocyclobutane is unstable and undergoes 
cycloreversion forming a new C=C bond and the volatile gas ethylene, as shown in  
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Scheme2A.4,7  Note that the mechanism is reversible and in order for the RCM 
reaction to be effective the equilibrium must be shifted into one direction i.e. to the 
right. Ring closing metathesis reactions are entropically driven in the forward 
direction because it ‘cuts’ one substrate into two products of which one is volatile 
(ethene) leaving the desired cycloalkenes to accumulate in the reaction mixture.4  
 
 
 
Scheme 2A4: Catalytic cycle of ring closing metathesis 
 
 
Early olefin metathesis catalysts were poorly defined. They were multicomponent 
homogenous and heterogeneous systems which exhibited ‘mixed’ Ziegler catalyst 
characteristics (high activity and incompatibility with most functional groups due to a 
strong Lewis-acidic and alkylating character).4 
 
In 1980, Schrock’s tetracoordinated alkylidene species of general formula 
[M(=CHCMe2Ph))=NAr)(OR)2] was described. This was an active and well defined 
catalyst (M=Mo or W and Ar and R are bulky substituents)8,9. Catalyst 2.8 in 
particular is the most active and is commercially available. However the reactivity of 
catalyst 2.8 is offset by the fact that it is sensitive towards moisture and oxygen it 
must therefore be handled in rigorously dried solvents using Schlenck techniques. 
Nevertheless catalyst 2.8 does have an advantage in its tolerance towards certain  
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functional groups that inhibit ruthenium-based metathesis catalyst (typically soft 
ligands such as sulfur and phosphine). 
 
N
i-Pri-Pr
MoO
O
CH3
PhCH3
F3C
CF3
F3C
F3C
2.8
 
 
The first well defined ruthenium catalyst complex (2.9) was reported in 1992 by 
Grubbs and co-workers.10 This catalyst has an advantage over 2.8 in that it is stable in 
protic solvents. The influence of the ligands on the activity of 5 coordinate 16 
electrons ruthenium complexes have been extensively studied.4,5,10 Consequently 
exchanging the triphenylphosphine (P(Ph)3) groups with larger and more basic 
tricyclohexylphosphine groups (P(Cy)3) (2.10) result in increased metathesis activity.4  
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Further work by Grubb and his colleagues has facilitated growth in the use of RCM in 
organic chemistry. Grubbs first generation catalyst 2.11 and Grubbs second 
generation catalyst 2.12 were introduced in the late 1990’s.10 These catalysts are 
commercially available with 2.12 being more reactive. Although on some occasion 
the ruthenium catalyst may not be as active as the early transition metal complexes 
and Schrock’s catalysts, they are more versatile in RCM application due to their 
improved functional group tolerance11. 
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Indeed Grubbs second generation catalyst is now widely used in RCM reactions.5,11 
The catalyst is less sensitive to air and moisture which makes it is easier to handle. 
The substitution of the P(Cy)3 with a more basic and sterically hindered N-
heterocyclic carbene (NHC) ligand increases the dissociation rate of the second 
phosphine ligand, resulting in the catalytic species (a 14 electrons ruthenium 
intermediate) being more easily formed. This results in increased catalyst life time 
and higher reactivity which in turn increases the ring closing metathesis activity. 
 
2.2.2 Microwave conditions 
 
Microwave activation has emerged as a powerful technique to promote a variety of 
organic reactions.12 RCM is generally carried out in homogenous solution at room 
temperature (or slightly higher) for several hours before the reaction goes to 
completion.  The yields of some reactions can be low and occasionally the reaction 
does not proceed under conventional heating methods, thus optimisation of the 
reaction was required.  
 
With microwave irridation as a heat source shorter reaction times can be achieved. In 
addition, reactions which are fail to occur using thermal heats can be achieve using 
microwave irridation.13 This is because the rapid uniform core heating associated with 
microwaves, instead of the concentration of heat around the reaction vessels walls 
help reduce catalyst decomposition.13,14,15 Apart from giving shorter reaction times, 
microwave irridation has also been shown to improve the yield of RCM reactions 
through a cleaner and more facile workup procedure.13,15 Over the past few years 
investigations into a combination of solvent-free conditions and microwave activation 
has resulted in significant progress towards the so called  ‘green chemistry’ eco 
methodology.16 For these reasons the use of microwave irridation has contributed 
significantly towards metathesis chemistry. 
 
The primary objective in this thesis is to apply and develop RCM methodology using 
microwave conditions for synthesis of β-strand macrocyclic compounds designed in 
section 2.1.   
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2.3 SYNTHESIS OF β-STRAND CONFORMATIONALLYCONSTRAINED
 ‘BIOACTIVE’ COMPOUNDS 
 
 
The use of ring closing metathesis is a very attractive method for synthesising 
peptidomimetics research, particularly those constrained into a desired ‘bioactive’ 
conformation.  
 
The objective of this research was to develop macrocyclic ring systems (15-22 
membered rings sizes) that conformationally lock the peptide backbone into the 
required bioactive β-strand conformation. These constrained structures pre-organise 
the inhibitor/substrate into a bioactive conformation and hence reduce the entropy of 
binding to the enzyme/protein (section 1.4.2). Furthermore, β-strand backbone 
macrocycles are attractive targets which may be employed as generic scaffolds 
facilitating the synthesis of different protease inhibitors. The synthesis of different 
protease inhibitors can be achieved by incorporating appropriate functionality or 
recognition elements to the key β-strand macrocyclic templates. Consequently a novel 
class of protease inhibitor is attained in a pre-organised ‘bioactive’ conformation 
which in turn can effectively bind to the protease active site. 
 
In this thesis the designed by the in silico studies (2.1-2.7) in section 2.1 were 
synthesised via RCM using Grubbs second generation catalyst and microwave 
irridation. The general approach was to construct a suitable tripeptide diene consisting 
of alkenes on the amino acids side chains P3 and P1 Chapter 3. A tripeptide backbone 
was chosen over dipeptide because modelling demonstrated them to mimic the linear 
β strand saw tooth conformation, thus allowing optimum hydrogen bonding with the 
enzyme active site. With the tripeptide backbone in place the next step is to cyclise 
the two terminal diene side chains by employing the RCM procedure (Chapter 4) as 
shown in Scheme 2B. Finally the successfully prepared macrocyclic compound was 
chemically modified into a calpain inhibitor by incorporating the desired warhead at 
the C terminus Chapter 5. 
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Scheme 2B: General approached of constructing macrocycle compounds 
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The selected macrocycle compounds 2.1-2.7 (sections 2.2) were synthesised. The 
syntheses are divided into two chapters (Chapter 3 and Chapter 4). Chapter 3 
illustrates the syntheses of β-strands tripeptide backbones 3.15, 3.21, 3.34, 3.44, 3.52, 
3.58, 3.64. These tripeptides β-strand backbones were successfully prepared by 
employing the general peptide coupling methods shown in Scheme 3.0  
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Scheme 3.0: General mechanisms of HATU coupling reactions 
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3.1 Synthesis of N-Boc-S-allyl-Cys-Val-S-allyl-Cys-OMe 3.15 
 
 
The diene 3.15 was prepared as shown in scheme 3.1. The amino acid 3.10 was 
allylated upon reaction with allyl bromide in alkaline conditions under an argon 
atmosphere to give N-Boc-S-allyl-Cys-OMe 3.11 in 77% yield (after silica gel-based 
column chromatography). The methyl ester of 3.11 was then hydrolysed by sodium 
hydroxide, methanol and water to give a free acid 3.12 in 83% yield. Next compound 
3.12 was coupled with (S)-Val-OMe hydrochloric salts using general coupling reagent 
HATU in basic conditions. Purification by column chromatography gave 3.13 in 66% 
yield. Compound 3.13 was then treated with sodium hydroxide, methanol and water 
to remove the methyl ester group to give compound 3.14 in 70% yield. The dipeptide 
3.14 diene was coupled to the (S)-N-allyl-Cys-OMe 3.26 (Scheme 3.4) using HATU 
coupling reagent and DIPEA to give an isolated diene 3.15 in 65% yield.  
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Scheme 3.1 Reagents and conditions: (i) allyl bromide, Et3N, DCM (77%) (ii) NaOH, 
MeOH, H2O, THF (83%), (iiii) Val-OMe.HCl, HATU, DIPEA, DMF (66%) (iv) 
NaOH, MeOH, H2O, THF (70%) (v) (S) allyl-Cys-OMe 3.35, HATU, DIPEA, DMF 
(65%)   
 
 
3.2 Synthesis of N-Boc-O-allyl-Ser-Val-S-allyl-Cys-OMe 3.21 
 
The synthesis of Boc-O-allyl-Ser-OMe 3.17 was attempted as shown in Scheme 3.2. 
Treatment of N-Boc-Ser-OMe 3.16 with sodium hydride as a base and allyl bromide 
resulted in mixtures of O-allylation, N-allylation and allylation at the methyl ester 
group. This may be due to the fact that the choice of sodium hydride as a base was too 
strong for this reaction, resulting in deprotonation as well as methyl ester hydrolysis. 
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 The second attempt was involved treating N-Boc-Ser-OMe with allyl bromide and a 
weaker base (triethylamine). This resulted in returned starting material only. 
 
BocHN O
O
OH
BocHN O
O
O
X
X
(i)
(ii)
3.16 3.17
 
 
Scheme 3.2 Reagents and conditions: (i) NaH, allyl bromide, DMF (0%) (ii) Et3N, 
allyl bromide, DCM (0%). 
 
The last attempt to synthesis compound 3.17 was carried out successfully by 
following the literature methods.1 N-Boc-Ser-OMe was treated with allyl ethyl 
carbonate (prepared in situ by reacting allyl alcohol, ethyl chloroformate at 00 C under 
basic conditions), allyl palladium chloride and triphenylphosphine to give N-Boc-O-
allyl-Ser-OMe 3.17 in 21% yield (unoptimised) after purification by column 
chromatography (Scheme 3.4). 
 
Allylation of 3.16 was carried out in neutral conditions to avoid deprotonation of the 
acidic proton from amine. Allyl ethyl carbonate, triphenylphosphine and allyl 
palladium (0) chloride dimmer catalyst reacted together to form the П-allylpalladium 
complex (Pd+).  This resulted in the release of ethylate compound which removed the 
proton from the side chain residue. Thus generate the nucleophile that readily 
underwent nucleophilic attack with an electrophile (Pd+ complex), resulted in the 
desired product 3.17 (Scheme 3.3). The yield obtained was relatively low compared 
to the literature.1 This could be because the reaction was carried out in a larger scale 
and the catalytic amount of palladium chloride may need to be increased. This should 
be taken into account and used for future reference. 
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Scheme 3.3: General mechanism of O-allylation with palladium chloride 1 
 
 
Next compound 3.17 was hydrolysed by treatment with sodium hydroxide, methanol 
and water to give compound 3.18 (82% yield). Dipeptide 3.19 was prepared by 
reacting free-acid 3.18 with (S)-Val-OMe.HCl, adopting the general coupling reagent 
HATU and a steric hindered base DIPEA in 73% yield (after purification by column 
chromatography). The methyl ester of 3.19 was hydrolysed to give 3.20 (71% yield) 
followed by the treatment with 3.35, HATU, DIPEA to give the desired isolated 
tripeptide compound 3.21 in 54% yield (Scheme 3.4). 
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Scheme 3.4 Reagents and conditions: (i) allyl alcohol, ethyl chloroformate, Et3N, 
ether 00C (ii) allyl palladium chloride, PPh3, THF (21%) (iii) 2M NaOH(aq), 
H2O/MeOH, THF (82%), (iv) (S)-Val-OMe.HCl, HATU, DIPEA, DMF (73%) (v) 
2M NaOH(aq), H2O/MeOH, THF (71%) (vi) (S)-allyl-Cys-OMe 3.35, DIPEA, DMF 
(54%) 
 
 
3.3 Synthesis of N- Boc-O-allyl-Glu-Val-S-ally Cys-OMe 3.34 
 
The allylation on the side chain of L-glutamic acid was attempted as shown in 
Scheme 3.5. The t-butyl ester from (L)-H-Glu-(OtBu)OMe 3.22 was removed under 
acidic condition by the treatment of 2M HCl in diethyl ether to give H-Glu-OMe 3.23 
98% yield. 
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The attempted synthesis of H-Glu-(allyl ester) OMe 3.24 was carried out by refluxing 
compound 3.23 with para-toluene sulfonic acid and allyl alcohol in benzene using 
Dean-Stark trap.2 Unfortunately, transesterification occurred and compound 3.25 was 
isolated instead of compound 3.24.  
 
OH2N
O
OO
OH2N
O
OO
OH2N
O
OHO
3.22 3.23
3.25(i)
OH2N
O
OO
3.24
(ii)
x
 
 
Scheme 3.5: Reagents and conditions: (i) 2M HCl diethyl ether (98%), (ii) para- 
toluene sulfonic acid, benzene, allyl alcohol, reflux 15h (15%) 
 
 
A new approach was carried out attempted using a different literature method3 and 
this successfully gave compound 3.27 (Scheme 3.6). As shown in Scheme 3.6 (L)-
glutamic acid 3.26 was selectively treated with chlorotrimethylsilane, allyl alcohol 
and purified by recrystallization with diethyl ether at 0o C to give the desired 
compound 3.27 in 77% yield. The N-terminus of 3.27 was then protected with di-tert-
butyl dicarbonate under Schotten Bauman’s conditions to give compound 3.28 in 80% 
yield. Next di-peptide 3.29 was synthesised by coupled compound 3.28 to (S)-Val-
OMe.HCl with HATU under basic conditions. Purification by column 
chromatography gave compound 3.29 in 50% yield. Attempts to hydrolyse methyl 
ester 3.29 using sodium hydroxide, methanol and water to give 3.30 were 
unsuccessful. Characterisation of the hydrolysed compound by 1H NMR (500 MHz) 
illustrated that both the allyl ester and the methyl ester groups had been removed. 
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The characterizations were carried out further by 13C NMR (75 MHz) and Low 
Resolution Mass spectrometry. The 13C NMR (75 MHz) illustrates missing peaks of 
the allyl group at δ 131.9, 117.9, 64.9 and the methyl ester peaks at and 51.7. The 
LRMS showed the presence of [ES+ M + [H+] found 347.2]. Consequently these 
characterizations suggested that the hydrolysis of dipeptide 3.29 have resulted in 
compound 3.31 where both allyl ester and methyl ester groups were being hydrolysed.  
 
 
This problem was overcome by changing the order of the synthetic steps. In 
particular, 3.28 was coupled to H-Val-allyl-Cys-OMe 3.33 using HATU under basic 
conditions to give the desired diene 3.34 in 40% yield after purification by column 
chromatography. Dipeptide 3.33 was synthesised from coupling (S)-N-Boc-Val-
OH.HCl to give 3.32 (88% yield after purification by column chromatography). Then 
Boc protecting group was removed by treatment with 4M HCl in dioxane yielding 
97% of compound 3.33.  
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Scheme 3.6 Reagents and conditions: (i) Chlorotrimethylsilane, allyl alcohol, 0o C 
diethyl ether (77%), (ii) Boc2O, Et3N, H2O/Dioxane (80%), (iii) (S)-Val-(OMe), 
HATU, DIPEA, DMF, (62%) (iv) NaOH, MeOH/H2O, THF (76%), (v) (S)-Boc-Val-
OH.HCl, HATU, DIPEA, DMF (88%), (vi) MeOH, SOCl2 (97%)  (vii) Boc-Allyl-
Glu-OH 3.28, HATU, DIPEA, DMF (38%)  
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Several attempts were made to remove the Boc protecting group from the N-terminus 
of compound 3.11 (Scheme 3.7). The first was to use 4M HCl in dioxane. This 
resulted a mixture of compounds 3.36 and 3.37. This is most likely due to traces of 
water in the dioxane, thus resulting in the formation of concentrated aqueous HCl. 
The second method attempted was the used of 2M HCl in diethyl ether resulting in the 
mixture of the starting material 3.11 and an ester hydrolysis. The desired compound 
3.35 was achieved by retreating this mixture with thionyl chloride in methanol in 79% 
yield. This treatment generated HCl in situ which allowed the Boc protecting group to 
be removed while at the same time re-esterifying the acid group. 
 
BocHN O
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S
H2N OH
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S
H2N O
O
S +
H2N O
O
S
3.36 3.37
(i)
(iii)
3.11 3.35
(ii)
 
 
Scheme 3.7 Reagents and conditions: (i) 4M HCl in dioxane (ii) 2M HCl in diethyl 
ether (iii) MeOH, SOCl2 0o C (79%). 
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3.4 Synthesis of N-Boc-N-allyl-Gln-Val-allyl-Gly-OMe 3.44 
 
The N-terminus of H-Glu-OMe 3.38 was protected on treatment of 3.38 with di-
tertiary-butyl-dicarbonate under Schotten Bauman’s condition to give compound 3.39 
79% yield after purification by column chromatography (Scheme 3.8).  Compound 
3.39 was then coupled to ally amine using coupling reagents EDCI, HOAT under 
basic conditions. Purification by column chromatography over silica gel-based gave 
3.40 (55% yield). Then methyl ester of 3.40 was hydrolysed by treatment with sodium 
hydroxide, methanol/water to give compound 3.41 (73% yield). Di-peptide 3.42 was 
prepared by coupling 3.41 to (S)-H-Val-OMe.HCl using HATU and DIPEA to give 
52% yield after purification by column chromatography. Subsequently 3.42 was 
hydrolysed with sodium hydroxide, methanol and water to give the free acid 
compound 3.43 (70%).  
 
Next, the C-terminus of commercially bought (S)-allyl glycine 3.45 was protected 
with methyl ester group by the treatment of 10% thionyl chloride in methanol at 00 C 
to give (S)-allyl Gly- OMe 3.46 (100%). The desired tripeptide was achieved by 
coupling between compound 3.43 and 3.46 using standard coupling reagent HATU 
with hindered base DIPEA. Purification by silica gel-based column chromatography 
gave compound 3.44 (34% yield). 
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Scheme 3.8 Reagents and conditions: (i) Boc2O, Et3N, Dioxane/H2O (79%) 3 (ii) allyl 
amine, EDC.HCl, HOAT, DIPEA, DMF (55%) (iii) NaOH, H2O, THF (73%) (iv) 
Val-OMe.HCl, HATU, DIPEA, DMF (52%) (v) NaOH, MeOH, H2O, THF (70%) (vi) 
(S) allyl-Gly-OMe, HATU, DIPEA, DMF (34%) (vii) MeOH, SOCl2 0o C (100%) 
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3.5 Synthesis of N-Cbz-N-allyl-Gln-Val-allyl-Gly-OMe 3.52 
 
Tripeptide 3.52 was synthesised as shown in Scheme 3.9. The amino acid 3.48 was 
prepared by coupling allyl amine to N-Cbz-Glu-OMe 3.47 using standard coupling 
reagents EDCI and HOBT under basic conditions in 88% yield after purification by 
column chromatography. Treatment of 3.48 with sodium hydroxide, methanol and 
water gave the amino acid 3.49 in 76% yield. Next 3.49 was coupled to (S)-H-Val-
OMe.HCl with the treatment of coupling reagent HATU and hindered base DIPEA to 
give compound 3.50 (80%) after purification by column chromatography. Compound 
3.50 was then hydrolysed to give dipeptide 3.51 (41%). Coupling between dipeptide 
3.51 and (S)-ally-Gly-OMe 3.46 with HATU and DIPEA resulted in an insoluble 
product possibly due to the present of the four amide bonds. A white solid formed 
during work-up in both of the EtOAC and 1M HCl aqueous layers. These white solids 
were collected using Buchner funnel, characterised by the 1H, 13C NMR and mass 
spectrometry giving the desired compound 3.52 in 83% yield. 
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Scheme 3.9 Reagents and conditions: (i)) allyl amine, EDC.HCl, HOBT, DIPEA, 
DMF (88%) (ii) NaOH, H2O, THF (76%) (iii) Val-OMe.HCl, HATU, DIPEA, DMF 
(80%) (iv) NaOH, MeOH, H2O, THF (41%) (v) (S)-allyl-Gly-OMe 3.46, HATU, 
DIPEA, DMF (83%) 
 
 
3.6 Synthesis of N-Boc-O-allyl-Tyr-Val-O-allyl-Glu-OMe 3.58 
 
N-Boc-O-allyl-Tyr 3.53 was coupled to (S)-Val-OMe.HCl using standard coupling 
procedure HATU under basic conditions to give compound 3.54 (40%) Scheme 3.10. 
Treatment of compound 3.54 with sodium hydroxide, methanol and water gave 
compound 3.55 in 78% yield. Next compound 3.56 was prepared by treating N-Boc-
O-allyl-Glu-OH 3.28 with diazomethane in diethyl ether at 00 C giving 3.56 in 93% 
yield. Then the N-terminus of 3.56 was removed by the treatment of 2M hydrochloric 
acid in diethyl ether giving compound 3.57 100% yield. The desired tripeptide 3.58  
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was achieved by coupling dipeptide 3.55 with 3.57 using HATU and DIPEA in an 
isolated 50% yield.  
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Scheme 3.10 Reagents and conditions: (i) (L)-Val-OMe.HCl, HATU, DIPEA, DMF 
(40%), (ii) NaOH, H2O, THF (78%) (iii) CH2N2, Et2O 00C (60%) (iv) 2M HCl in 
diethyl ether (100%) (v) HATU, DIPEA, DMF (50%)  
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3.7 Synthesis of 4-Fluoro-O-allyl-Tyr-Leu-ally Gly-OMe 3.64 
 
 
The desired Tri-peptide 3.64 was synthesised as shown in Scheme 3.11. N-Boc-O-
allyl-Tyr-OH 3.59 was coupled to (S)-Leu-OMe.HCl using the standard coupling 
procedure HATU under basic conditions to give dipeptide 3.60 in 59% yield (after 
purification by column chromatography). The 4-Fluoro-O-allyl-Tyr-Leu-OMe 3.62 
was synthesised by coupling with compound 3.61 (prepared by treated compound 
3.60 with 4M hydrochloric acid in 1,4-dioxane (100% yield) to 4-fluoro-benzene 
sulfonyl chloride under basic conditions. Purification via silica-gel based column 
chromatography gave 3.62 in 61% yield. This was then hydrolysed by the treatment 
of sodium hydroxide methanol and water to give compound 3.63 (94% yield). Next 
dipeptide 3.63 was coupled to (S)-allyl-Gly-OMe 3.46 using HATU and hindered 
base DIPEA to give the desired tripeptide 3.64 (75% yield after silica-gel based 
column chromatography). 
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Scheme 3.11 Reagents and conditions: (i) (S)-Leu-OMe.HCl, HATU, DIPEA (59%), 
(ii) 4M.HCl in dioxane (100%), (iii) 4-Fluoro-Benzene Sulphonyl Chloride , DIPEA, 
DCM (61%), (iv) NaOH, MeOH/H2O, THF (94%), (v) S-allyl-Gly-OMe 3.46, 
HATU, DIPEA, (75%) 
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3.8 SUMMARY OF CHAPTER THREE 
 
The target tri-peptide β-backbone 3.15, 3.21, 3.34, 3.44, 3.52, 3.58, 3.64 were 
successfully synthesised as summarised in Table 3.1.  
 
Table 3.1: Summary of %yield syntheses of Diene 
 
Compounds Yield (%) 
3.15 65 
3.21 54 
3.34 40 
3.44 30 
3.52 83 
3.58 50 
3.64 75 
 
The uronium salt HATU coupling reagent was chosen over the other uronium or 
phosphonium reagents (HBTU, HCTU, HDTU and PyAOP) due to its high yielding 
reactions, faster reaction times and minimisation of the loss of chiral integrity.4 
However in some coupling reaction the use of HATU reagent did not give the 
effective coupling yields (See Table 3.1 - 3.4 and 3.44). Perhaps it might be necessary 
to explore the use of other coupling reagents in order to enhance the results efficiency. 
Carpino et al. have illustrated that another class of peptide coupling reagents 
‘organophosphorous ester’ (For example; phosphate esters such as DepODhbt, 
DepOBt or phosphinyl esters such as DtpOAt) appears to be more reactive over the 
other coupling reagents.5,4 Consequently these new classes of coupling reagents are 
likely to be employed with the anticipation that they would offer better coupling 
yields whilst maintaining the chirality of the amino acid. 
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The terminal side chains of tripeptide dienes 3.15, 3.21, 3.34, 3.44, 3.52, 3.58, 3.64 
(Chapter 3) under went RCM to successfully yield the ring closed macrocyclic 
products 2.4, 2.5, 2.6, 2.7, and 4.6.  RCM was carried out using Grubbs second 
generation catalyst (2.12) with microwave irradiation as the heat source (1200W).  
The use of microwave irridation is a relatively new technique for especially within 
our group.1  Furthermore the application of RCM for the synthesis of 
conformationally constrained peptidomimetic compounds is still a largely unexplored 
area (section 2.2). Therefore one of the key objectives in this part of the work was to 
optimise the RCM reaction conditions via microwave irradiation to provide a standard 
methodology for the synthesis of conformationally constrained peptidomimetics. As 
described in section 1.3.2 and 1.4 peptidomimetics conformationally constrained into 
the ‘bio-active’ conformation are very attractive synthetic targets and the use of RCM 
is a very attractive method uses to synthesis such conformation.  Therefore the 
development of efficient methods for their synthesis is a very valuable and 
worthwhile explore.  
 
In this thesis we now report the development of new RCM reaction conditions using 
microwave irradiation for the cyclisation of peptide based diene precursors such as 
those described in Chapter 3.  
 
Two different reaction conditions were developed depending on the RCM substrate.  
One problem which is frequently occur when ring closing is applied to peptide based 
dienes, is the ability of substrate able to form catalyst deactivating six-membered 
chelate during the catalytic cycle (section 4.3).  The combination of microwave 
irradiation and addition of a Lewis acid (chlorodicyclohexylborane) is required to 
tackle such chelation problem. Consequently these reaction conditions then result in a 
productive RCM reaction.  Without the addition of Lewis acid, there is no reaction 
occurs and the diene can be recovered from the reaction mixture or one of diene 
participate in chelate formation and the other reacts with a complimentary olefin to in 
a intermolecular cross metathesis reaction.  Therefore neither the desired ring closed 
product is obtained nor the diene starting material recovered. 
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The peptide based dienes which are unable to form the chelate can be successfully 
ring closed without the need to add a Lewis acid.  The use of microwave irradiation is 
still required to obtain optimal yields with more efficient time.   
 
 
 
4.1 SYNTHESIS OF 15-MEMBERED CYSTIENE AND SERINE  BASED 
 MACROCYCLES (2.5 AND 2.6) 
 
 
4.1.1 N-Boc-Cys-Val-Cys-Macrocycle-OMe ( 2.5) 
 
Tripeptide 3.15 undergoes RCM using Grubbs second generation catalyst 2.12 in 
1,1,2-trichloroethane under microwave conditions for 30 min to yield macrocycle 4.1 
in an isolated yield of 33% (unoptimised) Scheme 4.1.1. 
 
The structure of macrocycle 4.1 was elucidated by proton NMR and mass 
spectrometry. The proton NMR showed the absence of multiplets (corresponding to 2 
x CH=CH2 protons) at 5.7ppm and multiplets at 5.2ppm (corresponding to 2 x 
CH=CH2 protons) from the diene 3.15. These protons are replaced by multiplets at 
5.4-5.46ppm representing a new CH=CH bond, existing in the same regions due to 
the symmetrical characters of the compound.   
 
The E/Z isomers of 4.1 were not separated and the compound was obtained in a 
mixture of E/Z geometric isomers. The COSY NMR displays overlap peaks of the α 
protons (Cys) 4.82ppm. The overlapped α protons (Cys) were coupled to two different 
NH at 7.07ppm and 7.35ppm thus suggested the present of such mixture isomers. 
These two NH peaks are exists in the ratio of 1:2. However it was not possible to 
identify which peaks represent the E/Z isomers and as such it is not possible to 
identify which isomer is the major isomer obtained.  
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Mass spectrometry confirmed the presence of desired product (LRMS [H+] of 4.1 is 
490.6 found 490.3). 
 
Attempts to hydrogenate the resultant carbon-carbon double bond using 10% 
palladium on carbon with methanol as solvent, under a hydrogen atmosphere, were 
unsuccessful, with starting material 4.1 being re-isolated quantitatively. The reason 
for this was probably the lack of solubility of compound 4.1 in methanol. 
 
The recovered starting material was resubjected to hydrogenation using a 
methanol/dichloromethane mixture (1:1).  This achieved the desired homogenous 
solution and yielded the desired saturated macrocycle 2.5 in 95% isolated yield.  
 
The structure of macrocycle 2.5 was characterised by NMR and mass spectrometry. 
The proton NMR displays missing CH=CH peak at 5.35-5.5ppm in 4.1. These 
CH=CH peak were replaced by CH2-CH2 peaks at 2.4-2.6ppm and 1.65-1.7ppm. 
Mass spectrometry confirmed the correct mass of 2.5 (LRMS [H+] 2.5 C21H37N3O6S2 
492.6 found 492.3). 
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Scheme 4.1.1: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
microwave 1200W, 1,1,2-TCE 30min (33%) (ii) 10%Pd/C, MeOH, H2 (0%), (iii) 
10%Pd/C, (1/1) MeOH/DCM, H2 (95%) 
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4.1.2 Synthesis of N-Boc-Ser-Cys-Val-OMe (2.6) 
 
Tripeptide 3.21 underwent RCM using Grubbs second generation catalyst 2.12 in 
1,1,2-trichloroethane under microwave conditions for 30 mins to yield macrocycle 4.2 
in an isolated yield of 14% (unoptimised) Scheme 4.1.2. 
 
 
 
The structure of macrocycle 4.2 was elucidated by proton NMR and mass 
spectrometry. The proton NMR showed the absence of multiplets corresponding to 
CH=CH2 protons at 5.78ppm, 5.85ppm and multiplets at 5.15-5.23ppm corresponding 
to 2 x CH=CH2 protons from the diene 3.21.These protons are replaced by multiplets 
at 5.46ppm and 5.62ppm corresponding to the new CH=CH protons.  
 
The E/Z isomers of 4.2 were not separated and the compound was obtained in a 
mixture of E/Z geometric isomers. The proton NMR shows splitting peaks from the 
Boc group at 1.4-1.5ppm suggested the present of such mixture isomers. These peaks 
have ratio of 1:3. However it was not possible to identify which peaks represent the 
E/Z isomers and as such it is not possible to identify which isomer is the major isomer 
obtained.  
 
Mass spectrometry confirmed the presence of desired product 4.2 (LRMS [H+] of 4.2 
is 474.6 found 474.5). 
 
The resultant carbon-carbon double bond in 4.2 was hydrogenated using 10% 
palladium on carbon under a hydrogen atmosphere in (1/1) methanol/dichloromethane 
solvent to give the desired macrocycle 2.6 in 53% yield. 
 
The structure of macrocycle 2.6 was characterised by NMR and mass spectrometry. 
The proton NMR displays missing CH=CH 5.46ppm and 5.62ppm in 4.2. The 
CH=CH peak were replaced by CH2-CH2 peaks at 2.5 and 1.6ppm. Mass  
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spectrometry confirmed the correct mass of 2.6 (LRMS [ES+ M + [H+] 2.6 Calcd for 
C21H37N3O7S 476.6 found 476.2).  
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Scheme 4.1.2: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
microwave 1200W, 1,1,2-TCE (14%) (ii) 10% Pd/C, (1/1) MeOH/DCM, H2 (53%) 
 
 
4.2 ATTEMPTED TO SYNTHESIS 15-AND 20-MEMBERED RINGS (4.3 
 AND 2.4) 
 
 
4.2.1 Attempted synthesis of N-Boc-Gln-Val-Gly-ene-Macrocycle-OMe (4.3) and 
Cbz-Gln-Val-Gly-ene-Macrocycle-OMe (2.4) 
 
Attempts to synthesise 15-membered rings 4.3 and 2.4 are shown in Scheme 4.2.1. 
Tripeptide dienes 3.44 and 3.52 were treated with Grubbs second generation catalyst 
(2.12) under microwave conditions for 30 mins. However the desired macrocycles 
were not obtained. See the later section (4.6) on the effect Lewis addition on RCM for 
details of how this problem was overcome. 
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Scheme 4.2.1: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
microwave 1200W, 1,1,2-TCE 30 mins (0%) 
 
4.2.2 Attempted synthesis of 20-membered N-Boc-Tyr-Val-Gly-ene-Macrcycle-
OMe (4.5) 
 
The attempted synthesis of the 20-membered ring 4.5 is shown in Scheme 4.2.2. The 
tripeptide diene 3.58 was treated with Grubbs second-generation catalyst 2.12 under 
microwave conditions for 30 mins.  Once again the desired macrocycle cycle was not 
obtained rather started material was recovered. 
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Scheme 4.2.2: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
microwave 1200W, 1,1,2-TCE 30 mins (0%) 
 
 
4.3 PROPOSED SIX-MEMBERED RING CHELATION 
 
 
There is a common theme found amongst the three tripeptide dienes 4.3, 2.4, 4.5 
shown in Schemes 4.2.1 and 4.2.2 that fail to undergo RCM.  All three dienes are 
capable of forming a six-membered chelate complex with the catalyst during the 
catalytic cycle. As shown in Scheme 4.3A the oxygen from the carbonyl is able to 
form a six-membered ring with the ruthenium catalyst.  The six-membered ring is 
thermodynamically stable and traps the ruthenium catalyst within the chelation thus 
preventing the next step in the  RCM cycle.2  
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Scheme 4.3A: Formation of six-membered ring via chelation of metal and carbonyl 
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Rather than the desired RCM reaction this chelation forces the equilibrium driven 
catalytic cycle to undergo an intermolecular cross metathesis reaction between the 
only two metathesis active olefins (Scheme 4.3B). 
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Scheme 4.3B: Intermolecular cross metathesis 
 
The chelation between the heterocyclic atoms to Grubbs catalyst has been shown to 
occur in cross metathesis systems3 where the non-productive chelation of the 
ruthenium carbonyl complexes was obtained.4  This type of chelation is commonly 
employed in the cross metathesis to promote selective CM reactions.3-6 However to 
the best of our knowledge this effect has not been recognised and applied to RCM 
reactions.   
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Several studies in the CM area have been carried out in an attempt to understand this 
chelation problem. In particular addition of Lewis acids such as Ti(OiPr)47,8,2 has been 
shown to suppress chelation between the carbonyl and ruthenium catalyst, thus 
facilitating the cleavage of this chelation.  Furthermore it has been shown that the use 
of Ti(OiPr)4 as an additive in RCM reactions does not always give a high product 
yield2. This therefore brought us to examine a difference type of Lewis acid for our 
investigations. We have chosen  the boron based Lewis acids rather than titanium or 
aluminium Lewis acids as additives in RCM reactions to facilitate cleavage of the 
proposed chelate complex. Our rationale for using boron based Lewis acids came 
from literature examples indicating that in the CM area boron based Lewis acids had 
significantly better product yields when compared with titanium or aluminium based 
Lewis acids.9  
 
 
4.3.1 Application of the proposed six-membered ring chelation  
 
A close examination of the structures of compounds 2.4, 4.3 and 4.5 reveals that the 
allyl glycine, allyl amide and allyl ester moieties are all capable of forming a six-
membered chelate to Grubbs catalyst in the first step of RCM (2+2 cycloadditions) 
see Scheme 4.3A. We proposed in section 4.3 that these types of compounds have a 
tendency to form the six-membered chelation to the ruthenium catalyst. Thus, 
addition of chlorodicyclohexylborane (Lewis acid) to the RCM reaction media would 
be expected to facilitate the cleavage of the ruthenium chelate, thus increased reaction 
yields should be observed Scheme 4.3.1. 
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Scheme 4.3.1: Proposed mechanism of chelation of Lewis acid in RCM  
 
The remaining sections in this chapter illustrates the application of 
chlorodicyclohexylborane (Lewis acid) catalyst on diene systems 3.52, 3.58 which 
failed to cyclise under a standard condition earlier in section 4.2.1 and 4.2.2 to 
promote productive RCM. The use of chlorodicyclohexylborane (Lewis acid) was 
also applied to the dienes system 3.34, 3.64 which are capable to form six-membered 
ring chelation to see if improved yield could be obtained.  
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4.4 SYNTHESIS OF 17-MEMBERED MACROCYCLES 2.7 AND 4.6 
 
 
4.4.1 Synthesis of N-Boc-Glu-Val-Cys-ene-Macrocycle-OMe (2.7 ) 
 
The tripeptide diene 3.34 undergoes RCM to form a 17-membered ring as shown in 
Scheme 4.4.1. RCM was performed using two different reaction conditions, 3.34 was 
subjected to RCM using Grubbs second-generation catalyst 2.12 both with and 
without the addition of the chlorodicyclohexylborane Lewis acid. In both cases the 
desired macrocycle was isolated.  Without the addition of the Lewis acid 2.7 was 
obtained in a 42% yield and with addition of the Lewis acid this was increased to 
50%. 
 
The structure was confirmed by NMR and mass spectrometry. LRMS of 2.7 gave M 
[H+] at 516.3, while the 13C NMR spectrum showed the absence of the CH=CH2 at 
118.5 and 117.9ppm. 1H NMR spectrum also showed the absence of doublets of 
doublets at 5.1ppm, 5.3ppm (corresponding to (Glu) CH=CH2 protons and (Cys) 
CH=CH2 respectively) and multiplets at 5.7ppm corresponding to the (Glu) CH=CH2 
proton and at 5.9ppm corresponding to the (Cys) CH=CH2 proton from the diene 3.34. 
These protons are replaced by two multiplets at 5.6ppm and 5.7ppm which represents 
the new carbon-carbon doubled bond formed. 
 
The E/Z isomer of 2.7 was not separated and the compound was obtained in a mixture 
of E/Z geometric isomers. The COSY NMR displays two different NH (Val) at 
6.84ppm and 6.88ppm. which suggested the mixture of such isomers. The two NH 
protons exist in a ratio of 1:2. However it was not possible to identify which peaks 
represent the E/Z isomers and as such it is not possible to identify which isomer is the 
major isomer obtained.  
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Scheme 4.4.1: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
1,1,2-TCE, chlorodicyclohexylborane (10%) microwave 1200W, 1h (50%) (ii) 
Grubbs second generation catalyst 2.12, 1,1,2-TCE, microwave 1200W, 1h (42%) 
 
4.4.2 Synthesis of 17-membered 4-F-Ph-SO2-N-Tyr-Leu-Gly-ene-Macrocycle-
OMe   (4.6) 
 
Diene 3.64 was subjected to RCM as shown in Scheme 4.4.2. Treatment with Grubbs 
second-generation catalyst 2.12 with the addition of Lewis acid 
(chlorodicyclohexylborane) under argon atmosphere afforded the macrocycle 4.6 in 
an isolated yield 65%. 
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Scheme 4.4.2: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
1,2,2-TCE, chlorodicyclohexylborane (10%) microwave 1200W, 1h (65%) (ii) 
Grubbs second generation catalyst 2.12, 1,1,2-TCE, microwave 1200W, 1h (29%) 
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The structure of the product was confirmed by NMR and mass spectrometry.  1H 
NMR spectrum showed the absence of doublets of doublets at 5.15ppm, 5.3ppm 
(corresponding to CH=CH2) and the two multiplets at 5.7ppm, 6.02ppm 
(corresponding to CH=CH2) from the diene 3.64. The two multiplets CH=CH2 
protons are replaced with the two multiplets at 5.4ppm and 5.8ppm representing the 
new carbon-carbon double bond.  
 
The E/Z isomer of 4.6 was not separated and the compound was obtained in a mixture 
of E/Z geometric isomers. The proton NMR displays two different peaks of NH (Leu) 
at 7.58ppm and 7.65ppm suggested the present of these isomers. The two peaks are 
roughly exists in the ratio of 1:15. However it was unable to identify which peaks are 
representing the E/Z isomers or whether which isomer are the major isomers obtained.  
 
Mass spectrometry also indicated desired product (LRMS M + [H+] is 516.4 found 
516.3).  
 
RCM of diene 3.64was also carried out in the absence of Lewis acid conditions by 
another group member, Joanna Duncan. The Macrocycle 4.6 was obtained in an 
isolated yield of 29%.   
 
 
4.5 ATTEMPTED SYNTHESIS OF 20-MEMBERED N-Boc-Tyr-Val-Gly-
ene-Macrcycle-OMe (4.5) 
 
The second attempt to synthesise the 20-membered macrocycle 4.5 was carried out as 
shown in Scheme 4.5. On this occasion RCM of the tripeptide diene 3.58 was 
attempted using the Chlorodicyclohexylborane Lewis acids conditions to cyclise 
dienes.  The diene was treated with Grubbs second generation catalyst in the presence 
of 10% Lewis acid (chlorodicyclohexylborane) under microwave conditions for 1h. 
However this still did not yield the desired macrocycle and instead starting material 
3.58 was obtained.  The reason for this is postulated to be that the addition of Lewis 
acid does not promote cleavage of the chelate to a sufficient level to favour the  
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intramolecular RCM.  It can only be concluded that this diene forms a particularly 
strongly bound chelate relative to other chelate examples outlined in this thesis or 
there could be other factors involved. 
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Scheme 4.5: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
chlorodicyclohexylborane (10%), 1,1,2-TCE, microwave 1200W 1h (0%) 
 
 
4.6 SYNTHESIS OF Cbz-Gln-Val-Gly-ene-Macrocycle-OMe (2.4) 
 
The desired macrocycle 2.4 was successfully synthesised as shown in Scheme 4.6. 
The tripeptide diene 3.52 was very polar and hence insoluble in organic solvent.  A 
homogenous solution was not achieved in 1,1,2-TCE, however the suspension was 
subjected to the optimised RCM conditions.  NMR of the crude reaction product 
indicated presence of desired product by the appearance of the missing diene peaks in 
3.52. The crude product 2.4 was not soluble in any of the following solvents; DCM, 
EtOAC, MeOH, THF or H2O. Therefore purification using standard forward phase 
column chromatography was not suitable. Purification of compound 2.5 using 
reverse-phase chromatography was attempted. However a suitable gradient could not 
be achieved that showed sufficient separation of the components. Hence purification 
using reverse-phase chromatography could not be performed. 
 
Another group member Kelly Anderson had previously demonstrated that purification 
of such polar peptides (tetrapeptide - hexapeptide) could be achieved using trituration.  
As such crude 2.4 was suspended in methanol, subjected to ultrasound for 15 mins  
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and then filtered through a grade 1 sinster under vacuum to obtain pure macrocycle 
2.4 in 14% isolated yield. 
 
The structure of 2.5 was confirmed using NMR and mass spectrometry. (LRMS M + 
[H+] is 503.5 found 503.4). 1H NMR shows the absence of multiplets at 5.75ppm and 
5.03ppm (corresponding to CH=CH2 and CH=CH2 respectively) from the diene 3.52. 
These protons peaks are replaced with two multiplets at 5.23ppm and 5.5ppm 
representing the new carbon-carbon double bond.  
 
The E/Z isomers of 2.4 were not separated and the compound was obtained as a 
mixture of E/Z geometric isomers. The COSY NMR displays two different α protons 
of Gln at 4.32ppm and 4.40ppm. These protons couple to overlapped NH protons at 
8.4ppm thus suggested the mixture of such isomers. The two α protons exist in a ratio 
of 1:2. However it was not possible to identify which peaks represent the E/Z isomers 
and as such it is not possible to identify which isomer is the major isomer obtained.  
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Scheme 4.6: Reagents and Conditions: (i) Grubbs second generation catalyst 2.12, 
chlorodicyclohexylborane (10%), 1,1,2-TCE, microwave 1200W 1h (14%) 
 
As stated above in section 4.2.1. RCM of diene 3.52 using standard RCM microwave 
reaction conditions was unsuccessful.  However adding 10% Lewis acid facilitates 
cleavage of the chelate and hence productive RCM. 
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4.7  SUMMARY AND FUTURE WORK OF CHAPTER 4 
 
RCM of cysteine and serine based macrocycles 2.5 and 2.6 was achieved albeit in 
relatively low yields (unoptimised). The reason for low yields with these substrates is 
due to the fact that the 1,1,2-TCE was not anhydrous and under microwave irradiation 
conditions a much faster rate of catalyst decomposition is observed. Therefore it is 
suggested that the RCM reaction of each of these substrates be repeated using the 
optimised reaction conditions before publication to obtain comparable results. 
 
The effect of using a Lewis acid additive (chlorodicyclohexylborane) on the yield of 
RCM is summarised in Table 4.1. From this it is clear that addition of the Lewis acid 
is beneficial.  In all cases (except compound 4.5) where the RCM reaction was 
performed in the presence and absence of the Lewis acid, improved isolated yields 
were obtained when the Lewis acid was added.  Furthermore in the case of 
macrocycle 2.4 RCM was only achieved with added Lewis acid. 
 
Table 4.1: Results Summary for RCM 
Compounds % Yield (with Lewis 
acid) 
% Yield (without 
Lewis acid) 
N-Boc-Cys-Val-Cys-ene-
Macrocycle-OMe (2.5) 
Not performed 33% 
N-Boc-Ser-Val-Val-Cys-ene-OMe 
(2.6) 
Not performed 14% 
N-Boc-Gln-Val-Gly-ene-
Macrocycle-OMe (2.3) 
Not performed  0% 
N-Boc-Tyr-Val-Gly-ene-
Macrocycle-OMe (4.5) 
0% 0% 
4-F-Ph-SO2-N-Tyr-Leu-Gly-ene-
Macrocycle-OMe (4.6)   
65% 29% 
N-Boc-Glu-Val-Cys-ene-
Macrocycle-OMe   (2.7) 
50% 42% 
Cbz-Gln-Val-Gly-ene-Macrocycle- 14% 0% 
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OMe (2.4) 
 
The results of this study strongly support the hypothesis that the use of Lewis acids to 
promote RCM in systems that contain structural features which can potentially form 
chelates with the ruthenium catalyst (section 4.3) is a valid one. 
 
However such a strategy does not appear to be suitable for all substrates.  Attempts to 
ring close macrocycle 4.5 with and without Lewis acid addition were not successful. 
This is probably because the chelate is simply too strongly “bonded” for the effect to 
be negated by the addition of a Lewis acid.  Indeed work by another member of the 
group (Steven Aitken) has demonstrated that the effect of chelate formation is 
particularly difficult to overcome when the heteroatom presents in both of the diene 
(Scheme 4.7A) as is the case with macrocycle 4.5 
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Scheme 4.7A: Formation of six-membered ring chelation where both diene consist of  
heteroatoms.     . 
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An alternative strategy to negate this problem, which would allow synthesis of 
macrocycles of the type 4.5, would be to employ cross metathesis instead of RCM to 
synthesise the macrocycle. As shown in Scheme 4.7B instead of synthesising a 
tripeptide diene it should be possible to prepare the required dipeptide olefins, 
perform CM and then cyclise using an intramolecular peptide coupling to form the 
desired macrocycle, thus avoiding the potential chelation problems. 
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Scheme 4.7.1: Proposed cross metathesis reaction 
 
The use of RCM chemistry is an attractive methodology for synthesising 
conformationally constrained peptidomimetics in a desired ‘bioactive’ conformation. 
We have successful synthesised the desired β-strand ‘bioactive’ macrocyclic 
compounds as summarised in Table 4.1.  
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5.1 CALPAIN INDUCED CATARACTS 
 
 
The anatomy of the eye is shown in (Figure 5A)1. It is one of the five senses that is 
vital for an individual. Sight is an astonishing process comprised of many parts of the 
eyes operationing together. Vision occurs when light enters the eyes, it is refracted by 
cornea and finally passes through the lens. The lens focuses this refracted light on to 
the retina where the light energy is converted into an electrical impulse. This electrical 
impulse is conducted through the optic nerves to the brain components where the 
image is interpreted.2  In a normal individual the lens is totally transparent.  Cataract 
is characterised by a disruption of this transparency.  
 
 
Figure 5A1 
 
The lens is situated behind the iris and is contained within a cell membrane; the lens 
capsule. It is an ellipsoid shape and it is layered in a similar manner to that of an 
onion.3  The lens is devoid of blood supply and at its centre (nucleus) it contains 
protein which has been present since birth.3 During development the cells elongate 
and lose organelles.  As a result this increases the protein content. A normal lens 
contains 35% (weight by weight) of protein.4 Eighty five percent of these proteins are 
the water-soluble proteins; lens crystallins (α, β, γ).4 The high concentrations of these 
proteins create a high degree of packing regularity thus this is what is responsible for 
lens transparency.1 
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Cataracts (Figure 5B5) are degenerative diseases where the lens in the eye becomes 
cloudy and prevents light from focusing to the retina.  This results in image distortion 
and eventually blindness. It is the primary cause of blindness world-wide and 
currently the only treatment for cataracts is surgical removal. 
 
 
 
Figure 5B5 An eye with cataracts 
 
The two main cataracts surgeries are intraocular lens implants (IOL implants) and 
phaco-emulsification surgery.4 Essentially IOL implants replace the original lens by 
inserting the polymer (made from polymethylmethacrylate (PMMA))4 into the 
capsular bag where it is held in place by the posterior capsule.6,7 In contrast 
contemporary phacoemulsification removes a cataract through a small incision made 
in the eye.  This method is now the preferred surgical procedure. In modern 
phacoemulsification surgery an ultrasound probe is used to break the lens (cataract) 
apart without harming the capsule.4 The use of this technology means that nowadays a 
much smaller incision is required.  It only needs to be big enough to remove the 
broken fragments out of the eye via aspiration.5,6 After removal of the fragments the 
foldable IOL implant is inserted through the same small incision. Once the inserted 
lens is inside it is unfolded to a normal IOL size and this is then held in place by the 
posterior capsule.6  
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Unfortunately the sad but true reality is that cataracts predominantly occur in the 
developing world.  India alone is a home of 23.5% of the world’s blind population.8 
At the present surgery still remains the only approach for cataract treatment.  Whilst 
this is now quite safe and very effective method the cost is extremely high. It has been 
estimated that cataract surgery worldwide created a device market of $2.2 billion in 
2000 and this was expected to increase to $2.5 billion by 2005.9 The expensive cost of 
surgery, together with often long waiting periods, means that for a number of patients 
the disease continues to develop and within a relatively short period lead to blindness.  
It is therefore highly desirable that an ideal drug is developed  to stop cataract 
formation, or at the very least slow the progression of human cataract. Consequently, 
the successful drug developed would improve the quality of life for people who can 
not afford surgery such as those in the developing world, or those who have a 
substantial wait before surgery can take place.  
 
Results obtained from an enormous amount of research suggest that calpains (section 
1.2-1.3) are implicated in cataract formations.10,11,12 Calpain is a calcium dependent 
cysteine protease catalysed the breakdown of the  major lens proteins; crystallins. The 
hypothesis is therefore, that calpain activation is induced by the elevated levels of 
calcium in the lens. This elevation in calcium levels is known be stimulated by a 
number of factors such as cellular aging, ultra violet radiation and diabetes. Thus the 
net result is formation of opacity in the lens and ultimately if untreated, blindness. 
Consequently, calpain inhibitors could provide a potential therapeutic approach for 
treatment of cataract.  Furthermore these same calpain inhibitors could in theory also 
be useful to treat other diseases that believed to be cause by overactivated calpain. To 
date there are no calpain inhibitors approved for human use for any therapeutic 
indication.  Thus the development of such inhibitors is an extremely worthwhile 
undertaking. 
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5.2 DESIGNED AND SYNTHESIS CALPAIN INHIBITOR VIA β-STRAND 
MACROCYCLE 
 
 
For the past few years at Canterbury University the Abell calpain group has 
synthesised and tested novel calpain inhibitors. The primary objective of this research 
project is to discover peptidomimetic compounds that mimic β-strands and are potent 
calpain inhibitors (see each for discussion).  It is then envisaged that the inhibitors 
discovered will be used to develop a pharmaceutical treatment for cataracts. 
 
Initially our peptidomimetic design work used a potent calpain inhibitor [SJA 6017-
IC50 7.5 nM (1.3)] reported by Senju pharmaceutical company13 as a lead compound 
from which to design novel calpain inhibitors.  
 
 
S
H
N
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Dipeptide based inhibitors based on SJA 6017, developed in our laboratories can be 
divided into three segments Figure 5C: 
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Figure 5C: Typical dipeptide calpain inhibitor 
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1) Address Region: Typically a hydrophobic group such as an aromatic group  
2) Peptide backbone: A dipeptide that adopts a β-strand conformation. 
3) Warhead: An electrophilic species which forms a covalent intermediate from 
the nucleophilic attack of the sulphur group of cysteine in the active site of the 
enzyme. Typically an aldehyde is used. 
 
A large number of these types of peptidomimetic compound have been synthesised 
and tested within our group.14,15,16  Compounds of this class have been termed as ‘first 
generation calpain inhibitors’.  The first generation compounds are flexible dipeptide 
molecules which exhibit variety conformations. It is postulated that there is only one 
conformation that is accountable for its biological activity and therefore a classical 
way in which medicinal chemists approach such a problem is to conformationally 
constrain the molecule into the ‘bioactive’ conformation.  Furthermore it would be 
expected that simple dipeptides, such as the first generation calpain inhibitors, would 
be poor drug candidates as they have poor pharmacokinetic profiles.  
 
Recently, the focus of our efforts has been devising a strategy that is capable of 
synthesising novel inhibitors conformationally constrained into the ‘bioactive’ 
conformation as discuss in this thesis.  Such compounds have been termed ‘second 
generation calpain inhibitors’. Only a small number of the macrocycles shown to be 
potential β-strand mimics in-silico has been synthesised.  The reason for this is simply 
due to the fact that new RCM methodology was required (section 2.2 and Chapter 4). 
RCM is a relatively new methodology in organic synthesis however work performed 
in Chapter 4 of this thesis in someway contributed to the understanding of why RCM 
is not successful on some diene.  We have now successfully devised methods to 
counteract the chelation between Grubbs catalyst and the carbonyl containing 
functional group. Consequently RCM chemistry used to form our macrocycles is now 
very efficient.  Furthermore it is anticipated this methodology will allow successful 
synthesis of a variety of potential macrocyclic calpain inhibitors constrained into the 
‘bioactive’ conformation.  
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5.2.1 Designing calpain inhibitor 
 
It is envisaged that the β-strand backbone macrocycles may be employed as generic 
scaffolds for the synthesis of different protease inhibitors.  This will be achieved by 
appending appropriate functionality/recognition elements to the key β-strand 
macrocyclic templates (Section 1.3.2). 
 
An investigation of the structure activity relationships (SAR) for calpain inhibitors17 
has shown that the optimal group at the address region/P3 position is the 4-Fluoro-
benzene-sulfonamide and at the P1 position an aldehyde warhead is required.   
 
Consequently appending these groups onto the macrocyclic intermediate 4.6 was an 
attractive target as a calpain inhibitor. This was achieved in three steps; firstly 4.6 was 
hydrogenated using Pd/C catalysis, secondly the methyl ester was then reduced to an 
alcohol and finally oxidation of alcohol to an aldehyde to yield macrocycle 2.2.  
Molecular modelling (Chapter 2) of macrocycle 2.2 suggests that this should be an 
excellent β-strand mimic as the Boltzmann weighted distribution shows that 2.2 is 
over 90% β-strand.   
 
As shown in Figure 5D the macrocycle 2.2 (grey) superimposed with SJA 6017 (1.3) 
(black).  From this it is clear that 2.2accurately confine the backbone to adopt the 
requisite β-strand ‘bioactive’ conformation.  
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Figure 5D: Superimposition between macrocycle 2.2 (grey conformer) and SJA6017 
(black conformer) and macrocyclic. 
 
 
Furthermore the Induced Fit Docking protocol (by Blair Stuart and Axel Neffe) 
indicates that 2.2 is not only a good β-strand mimic but the docking score (binding 
energy calculated using GLIDE and PRIME) indicates that this will be a potent 
calpain inhibitor. The docking of 2.2 into the enzyme is shown in Figure 5E. This 
clearly shows that the macrocycle is bound in an also perfect β-strand conformation.  
Figure 5E also shows that aldehyde warhead is in close proximity to the active site of 
Cys residue (4.06Å). 
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Figure 5E: Docking of 2.2 with the aldehyde warhead positions proximity to cysteine 
residue (4.06Å). 
 
5.2.2 Synthesis of Macrocycle 4-F-SO2-N-Tyr-Leu-Gly-ene-Macrocycle-CHO 
calpain inhibitor (2.2). 
 
For the large scale synthesis of 2.2 for the in-vivo sheep trial I supplied Janna Nikkel 
with a quantitative quantity of 4.6.  This was converted into the calpain inhibitor in 
three steps (Scheme 5.1).  4.6 was hydrogenated using 10% palladium on carbon 
under a hydrogen atmosphere in a methanol/dichloromethane/ethyl acetate mixture to 
afford the isolated saturated macrocycle 5.1 in 95% yield.  Reduction of the methyl 
ester using to the alcohol 5.2 was achieved using LiALH4 in THF (92%). Oxidation 
using sulfur trioxide pyridine complex and DIPEA in a mixture of DCM and DMSO 
afforded 2.7 in 45% yield. 
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Scheme 5.1: Conversion to calpain inhibitor by Janna Nikkel 
 
 
 
 
5.3 BIOLOGICAL ASSAY FOR CALPAIN INHIBITOR18,19,20 
 
 
The inhibition constant (IC50) value of 2.2 was determined using in vitro assay.  The 
IC50 is the concentration of the inhibitor required to inhibit the activity of an enzyme 
by 50%. The assay employed herein is a fluorometric one. 4,4-difluoro-5,7-dimethyl-
4-bora-3a,4a-diaza-s-indacene-3-propionic acid (BODIPY) florophore casein labelled 
(BODIPY-FL-casein)18 is used a the fluorophore.  
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The assay was performed by Janna Nikkel at Lincoln University. The purified m-
calpain obtained from sheep lung and suitable blanks (EDTA and Calcium) along 
with the m-calpain control solution were prepared by our collaborators at Lincoln 
University.  
 
The assay was carried out in a black BMG fluorometric plate reader. A black 
microtiter plate was used to minimise background florescence and interference 
between the wells. The blanks (EDTA and Calcium), m-calpain control solution and 
inhibitor containing solutions were added to the well in triplicate. Once the BODIPY 
FL-Casein substrates were added, the well plates were immediately inserted to the 
BMG fluorescence reader. Fluorescence from an individual well was determined at 
485 nm excitation and 538 nm emission.  Fluorescence units (FU) were recorded 
every 1-1.5 minutes for period of time 10-20minuites.  
 
The IC50 of the enzymatic inhibition activities was calculated by taking the average 
change in fluorescence reading (FU) obtained from the three wells together  with the 
average sum of fluorescence obtained from the three blanks (EDTA and Calcium) as 
shown in Equation 5.1.  
 
FUsample = FUmean total – FU(Ca  + EDTA)/2 
Equation 5A 
 
The percent inhibition of m-calpain for each compound was calculated using 
Equation 5.2 
 
% Inhibition = ((FUcalapain 2 – FUsample)/FUcalpain 2) x 100 
Equation 5B 
 
The assay data obtained were analysed using the graphical program in Microsoft 
Excel.  Percentage inhibition vs. log of inhibitor concentration as plotted. Linear best 
fits were obtained and the IC50 values were determined by extrapolating the x-axis log 
value and converting back to units of concentration.   
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The assay results obtained from macrocycle 2.2 reveals the IC50 values of 45nM. This 
is one the most potent conformationally constrained β-strand calpain inhibitors 
synthesised within our group. Furthermore this conformationally constrained β-strand 
mimic have also shown a significant decreased in the IC50 values compared to the 
dipeptide calpain inhibitors discuss earlier in section 1.3.2. As such the utilisation of 
conformationally constrained approached does indeed optimised the inhibitors 
potency. 
 
 
 
5.4 SUMMARY AND FUTURE WORK 
 
 
RCM has been used to synthesise macrocyclic compounds which were designed with 
the aid of molecular modelling to be conformationally constrained into β-strand 
‘bioactive’ conformation. By appending appropriate functionality on to the 
macrocyclic intermediate a potent calpain inhibitor (2.2) was obtained.  The IC50 
value of macrocycle 2.2 found to be 45 nM and this value is one of the best to date 
that represents a significant step forward in the design calpain inhibitors.  This 
compound is currently undergoing in vivo evaluation by our collaborating group at 
Lincoln University  
 
In addition to the synthesis of calpain inhibitors, it is proposed that by appending 
appropriate functionality to the β-strand macrocyclic intermediates, these macrocyclic 
templates can be modified to inhibit a wide variety of proteases.  
 
Thus by appending the calpain specific moieties as in 2.2, it is expected that the 
macrocyclic intermediates from chapter 4 (2.3, 2.5 and 2.6) can be elaborated into 
potent calpain inhibitors. 
 
The macrocyclic templates prepared in this thesis also provide both the methodology 
and synthetic route with the attempt to validate the generic β-strand protease inhibitor 
design strategy.  An example of such approached is shown in Scheme 5.2.  
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Incorporating the required additional recognition moieties known to confer HIV-1 
protease inhibition to one our macrocycles should result in the synthesis of a potent 
HIV-1 protease inhibitor 
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Scheme 5.2: Proposed of possible Aspartic protease inhibitor-HIV inhibitor 
 
The successful synthesis of 2.2 and its potent IC50 value against calpain makes a 
compelling case that the combination of a β-strand conformational constraint strategy 
together with the use of molecular modelling to design β-strand mimics is a 
methodology which could well confer the synthesis of generic protease inhibitor 
templates.  
 
The key reaction in which allowed the efficient synthesis of 2.2 was without doubt is 
the RCM step.  The significant success of this synthesis is due to our new 
methodology of combining a Lewis acid additive (chlorodicyclohxyl borane) and 
microwave irradiation (1200W).  Once more this is a very significant result and one 
which will probably find extensive use particularly in the field of conformationally 
constrained peptidomimetics. 
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6.1 GERNERAL METHODS AND EXPERIMENTAL PROCEDURES 
 
General Experimental Methods 
 
Unless otherwise indicated all experiments were performed in oven-dried glassware. 
Solvents and reagents used in reactions were purified according to literature 
procedures.1 Dichloromethane and 1,1,2 Trichloroethane were distilled from calcium 
hydride. Tetrahydrofuran was distilled from sodium and benzophenone. 
Dimethylformamide was obtained dry from Aldrich and stored under argon. 
Petroleum ether describes a mixture of hexanes in the boiling point range 50-70oC.  
 
Thin-Layer Chromatography (TLC) 
Analytical thin layer chromatography was conducted on plastic backed Macherey-
Nagel SIL G/UV254 plates. Visualisation was by ultraviolet light and/or potassium 
permanganate solution and/or PMA. 
 
Flash Column Chromatography 
Flash chromatography was performed on Merk silica 60 using a Buchi sepacore 
automated flash chromatography system. All eluting solvents were distilled before 
use. 
 
Nuclear Magnetic Resonance 
Proton (1H) detected NMR spectrums were obtained either on a Varian UNITY 300 
spectrometer at 300 MHz or a Varian INOVA 500 spectrometer at 500 MHz. All 
carbon (13C) detected NMR spectrums were obtained on a Varian XL300 
spectrometer operating at 75 MHz. Spectra were obtained at 23oC. Chemical shifts 
were reported in parts per million (ppm) on the δ scale.  
 
Mass Spectrometry 
Mass spectra were carried out by Bruce Clark (University of Canterbury) using the 
Micromass LCT mass spectrometer. The spectrums were processed via MassLynx 3.5 
Global editions.  
 
Melting Point (mp) 
Melting points were taken on an electrothemal apparatus without being corrected. 
Chapter 6 - Experimental  
_____________________________________________________________________ 
87 
 
General Procedure A: Peptide Coupling Using HATU 
To a stirring solution of the acid (1equiv) in dry DMF at room temperature was added 
HATU (1.1 equiv). After 5 min, the amine (2 equiv) was added followed by DIPEA 
(4 equiv) and the solution was continued to stir for 18hr. The DMF was removed by 
diluting with a large amount of ethyl acetate and partition with 1M HCl. The organic 
phase was washed sequentially with 1M HCl (aq), brine and dried over magnesium 
sulphate. The solvent was removed in vacuo to yield the crude peptide compound 
which can be purified by flash column chromatography on Merk silica gel 60. 
 
General Procedure B: Peptide Coupling Using EDC/HOAT 
To a stirring solution of the acid (1equiv) in dry DMF at room temperature was added 
EDC (1.1 equiv), HOAt (1.1 equiv). After 5 min, the amine (2 equiv) was added 
followed by DIPEA (4 equiv) and the solution was continued to stir for 18hr. The 
DMF was removed by diluting with a large amount of ethyl acetate and partition with 
1M HCl (aq). The organic phase was washed sequentially with 1M HCl (aq), brine and 
dried over magnesium sulphate. The solvent was removed in vacuo to yield the crude 
peptide compound which can be purified by flash column chromatography on Merk 
silica gel 60. 
 
General Procedure C: Methyl Ester Hydrolysis 
A solution of 2M sodium hydroxide (2.5 equiv) was added to a solution of methyl 
ester (1 equiv) in THF. The minimum amount of H2O/MeOH was added to obtain a 
homogenous solution. The mixture was stir for 15hr and the solvent was removed 
under reduced pressure. The residue was partitioned between ethyl acetate and 10% 
citric acid and the aqueous phase was extracted twice more with ethyl acetate. The 
combined organic extracts were washed with 2x brine, dried over magnesium sulphate 
and filtered. The solvent was removed in vacuo to yield the crude acid. 
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General Procedure D: Ring Closing Metathesis I 
The Diene was dissolved in 1,1,2-Trichlorethane (0.01M). To this a portion (10%mol) 
of Grubbs second generation catalyst was added. The solution was heated at reflux in 
the microwave (1200 W) for 10 minutes. Two further additions of Grubb’s second 
generation catalyst (2.12) (2x10%) were added, after each the reaction mixture was 
subjected to 10 minutes heating in the microwave. The resulted solution was 
concentrated in vacuo to yield crude product which was purified via silica gel-based 
column chromatography. 
 
General Procedure E: Ring Closing Metathesis I 
The Diene was dissolved in 1,1,2-Trichlorethane (0.01M) under argon atmosphere. To 
this a portion (10%mol) of Grubbs second generation catalyst (2.12) was added. The 
solution was heated at reflux in the microwave (1200 W) for 20 minutes. Two further 
additions of Grubb’s second generation catalyst (2x10%) were added, after each the 
reaction mixture was subjected to 20 minutes heating in the microwave. The resulted 
solution was concentrated in vacuo to yield crude product which was purified via 
silica gel-based column chromatography. 
 
General Procedure F: Ring Closing Metathesis III (Lewis Acid) 
The Diene was dissolved in 1,1,2-Trichlorethane (0.01M) under argon atmosphere. To 
this a portion (10%mol) of Grubbs second generation catalyst (2.12) and (10% mol) 
chlorodicyclohexylborane Lewis acid were added. The solution was heated at reflux 
in the microwave (1200 W) for 20 minutes. Two further additions of Grubb’s second 
generation catalyst (2x10%) were added, after each the reaction mixture was 
subjected to 20 minutes heating in the microwave. The resulted solution was 
concentrated in vacuo to yield crude product which was purified via silica gel-based 
column chromatography. 
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6.2 EXPERIMENTAL DESCRIBED FROM CHAPTER 3 
 
Synthesis N-Boc-S-allyl-Cys-OMe (3.11) 
 
H
N O
O
S
O
O
3.11
 
 
To a stirred solution of N-Boc-L-Cys-OMe 3.10 (5.50g, 23.4mmol) in dry DCM 
(30mL) under argon atmosphere was added allyl bromide (2.5mL, 25mmol) and 
triethylamine (1.4mL, 25mmol). The white precipitation was formed and the resulting 
solution was stirred for 15hr. The solvent was removed in vacuo and the residue was 
partition between ethyl acetate (25mL) and 1M HCl (aq) (15mL). The organic phase 
was washed with brine (2 x 15mL), dried over MgSO4 and filtered through fluted 
filter paper. Removal of solvent gave white residue which was purified by column 
chromatography Rf = 0.26 (1/6 (EtOAc / (50/70) Petroleum ether)). The column was 
eluting with gradient of (50/70) Petroleum ether) to (1/5 (EtOAc / (50/70) Petroleum 
ether)) to give a white solid compound 3.11 (4.9g, 18mmol, 77%): 
1H NMR (500 MHz) (CDCl3) δ 5.64 (dt, 1H, J=7.4Hz, J=15.4Hz, 1H, CH=CH2), 5.36 
(d, 1H, J=7.1Hz, NH), 5.02 (dd, 2H, J=7.0Hz, J=8.7Hz, CH=CH2), 4.39 (d,1H, 
J=5.5Hz, α CH), 3.64 (s, 3H, OCH3), 3.02 (m, 2H, SCH2), 2.77 (ddd, 2H, J=4.6Hz, 
J=13.9Hz, J=18.9Hz, CH2S), 1.34 (s, 9H, C(CH3)3);  
13C NMR (75 MHz) (CDCl3) δ 171.5, 155.4, 133.5, 117.6, 80.2, 53.0, 52.3, 34.9, 
32.6, 28.2;  
LRMS [ES+ M + [H+] Calcd for C12H21NO4S 276.3 found 276.2]. 
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Synthesis N-Boc-S-allyl-Cys-OH (3.12) 
 
H
N OH
O
S
O
O
3.12
 
 
N-Boc-S-allyl-Cys-OMe 3.11 (4.9g, 18mol) was hydrolysed according to general 
procedure C to give oily compound 3.12 (3.86g, 15mmol, 83%):  
1H NMR (500 MHz) (CDCl3) δ 5.73 (dt, 1H, J=7.3Hz, J=16.9Hz, CH=CH2), 5.40 (d, 
1H, J=7.7Hz, NH), 5.11 (dd, 2H, J=7.0Hz, J=8.7Hz, CH=CH2), 4.52 (d, 1H, J=6.8Hz, 
α CH), 3.13 (d, 2H, J=7.2Hz, SCH2), 2.91 (ddd, 2H, J=5.0Hz, J=14.1Hz, J=19.6Hz, 
CH2S), 1.43 (s, 9H, C(CH3)3);  
13C NMR (75 MHz) (CDCl3) δ 175.1, 155.3, 133.5, 117.8, 80.4, 52.9, 35.0, 32.4, 
28.2;  
LRMS [ES+ M + [H+] Calcd for C11H19NO4S  262.3 found 262.1] 
 
Synthesis N-Boc-S-allyl-Cys-Val-OMe (3.13) 
 
H
N
N
H
O
S
O
O
O
O
3.13
 
 
N-Boc-S-allyl-Cys-OH 3.12 (3.76g, 14mmol) was coupled to (S)-Val-OMe.HCl 
(4.8g, 29mmol) according to general procedure A gave a crude white residue Rf = 
0.36 (1/3 EtOAc / (50/70) petroleum ether). Purification was achieved by column 
chromatography, eluting with a gradient of (50/70) Petroleum ether) to (1/1 (EtOAc / 
(50/70) Petroleum ether)) to give a white solid compound 3.13 (3.6g, 9.6mmol, 66%):  
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1H NMR (500 MHz) (CDCl3) δ 6.87 (bs, 1H, Val(NH)), 5.78 (tdd, 1H, J=7.2Hz, 
J=9.9Hz, J=17.1Hz, CH=CH2), 5.34 (bs, 1H, Boc(NH)), 5.15 (dd, 2H, J=13.4Hz, 
J=26.4Hz, CH=CH2), 4.51 (dd, 1H, J=4.9Hz, J=8.7Hz, Val α (CH)), 4.25 (d, 1H, 
J=6.5Hz, Cys α CH), 3.72 (s, 3H, OCH3), 3.17 (dd, 2H, J=4.3Hz, J=6.7Hz, SCH2), 
2.83 (ddd, 2H, J=6.3Hz, J=13.9Hz, J=47.0Hz, CH2S), 2.17 (m, 1H, Val(CH)), 1.45 (s, 
9H, C(CH3)3), 0.92 (dd, 6H, J=6.9Hz, J=12.2Hz, Val(CH3)2); 
13C NMR (75 MHz) (CDCl3) δ 171.9, 170.6, 155.4, 133.8, 117.9, 80.4, 57.3, 53.8, 
52.6, 35.1, 32.7, 31.2, 28.2, 18.9, 17.7; 
LRMS [ES+ M + [H+] Calcd for C17H30N2O5S 375.5 found 375.3];  
mp = 140-145 0C  
 
Synthesis N-Boc-S-allyl-Cys-Val-OH (3.14) 
 
H
N
N
H
O
S
O
O
OH
O
3.14
 
 
N-Boc-S-allyl-Cys-Val-OMe 3.13 (2.8g, 7.5mmol) was hydrolysed following general 
procedure C to give white gluey compound 3.14 (1.88g, 5.2mol, 70%): 
1H NMR (500 MHz) (CDCl3) δ 7.04 (bs, 1H, Val(NH)), 5.77 (m, 1H, CH=CH2), 5.45 
(bs, 1H, Boc(NH)), 5.16 (ddd, 2H, J=7.6Hz, J=7.6Hz , J=18.0Hz, CH=CH2), 4.54 
(dd, 1H, J=4.6Hz, J=8.5Hz, Val α (CH)), 4.31 (d, 1H, J=6.9Hz Cys α (CH)), 3.16 (d, 
2H, J=6.9Hz, SCH2), 2.84 (ddd, 2H, J=6.6Hz, J=13.1Hz, J=18.7Hz, CH2S), 2.26 
(m,1H, (Val(CH)), 1.45 (s, 9H, C(CH3)3), 0.97 (dd, 6H, J=6.6Hz, J=14.1Hz, 
Val(CH3)2); 
13C NMR (75 MHz) (CDCl3) δ 174.6, 171.6, 155.7, 133.7, 117.9, 80.2, 57.2, 53.8, 
35.1, 32.6, 30.9, 28.2, 18.9, 17.6;  
LRMS [ES+ M + [H+] Calcd for C16H28N2O5S 361.5 found 361.3]. 
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Synthesis N-Boc-S-allyl-Cys-Val-S-ally-Cys-OMe (3.15) 
 
H
N
N
H
O
S
O
O
H
N
O
O
O
S
3.15
 
 
N-Boc-S-allyl-Cys-Val-OH 3.14 (0.94g, 2.6mmol) was coupled to S-allyl-Cys-OMe 
3.35 (0.91g, 5.2mmol) according to general procedure A gave white residue Rf = 0.28 
(1/2 EtOAc / (50/70) petroleum ether). Purification was achieved by column 
chromatography, eluting with gradient of (50/70) Petroleum ether) to 100% EtOAc to 
give a white solid compound 3.15 (0.86g, 1.7mmol, 65%):  
1H NMR (500 MHz) (CDCl3) δ 7.01 (d, 1H, J=7.1Hz, Val (NH)),  6.92 (d, 1H, 
J=8.7Hz, NH), 5.73 (m, 2H, CH=CH2), 5.46 (d, 1H, J=7.4Hz, Boc (NH)), 5.11 (m, 
4H, CH=CH2), 4.74 (dd, 1H, J=5.8Hz, J=13.4Hz, Cys α (CH)), 4.39 (m, 1H, Val α 
(CH)), 4.28 (d, 1H, J=5.4Hz, Cys α (CH)), 3.73 (s, 3H, OCH3), 3.10 (ddd, 4H, 
J=6.9Hz, J=16.7Hz, J=20.6Hz, 2(SCH2)), 2.85 (m, 4H, 2(CH2S)), 2.17 (m, 1H, 
Val(CH)), 1.43 (s, 9H, C(CH3)3), 0.94 (m, 6H, Val(CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 170.9, 170.7, 170.5, 155.7, 133.7, 133.5, 117.9, 117.9, 
80.1, 58.4, 53.9, 52.5, 51.5, 35.1, 34.9, 32.3, 30.9, 30.7, 28.2, 19.1, 17.8; 
LRMS [ES+ M + [H+] Calcd for C23H39N3O6S2 518.7 found 518.3]. 
 
Synthesis pf N-Boc-O-allyl-Ser-OMe (3.17) 
 
H
N
O
OO
O O
3.17
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Allyl ethyl carbonate was made in situ. To a stirring solution of allyl alcohol (1.97mL, 
29mmol) and ethyl chloroformate (3.12mL, 32.7mmol) at 00C in diethyl ether (20mL) 
was added dropwised triethylamine (4.57mL, 32.8mmol). The solution was leaved to 
stir for 20min and resulted white precipitate formation which was removed by 
filtering through Buchner funnel. The filtrate was collected and the ether solvent was 
removed by purged with nitrogen for 1-2h. Next the resulted solution was dissolved in 
THF (4mL). To this a solution of allyl palladium chloride dimmer (0.083g, 
0.23mmol) and triphenylphosphine (0.3g, 1mmol) in THF (3mL) was added. The 
solution mixtures were added to a stirring solution of N-Boc-Ser-OMe (5.0g, 
2.3mmol) in THF (20mL). The solution was leaved to stir for 18h and the solvent was 
removed in vacuo resulted crude yellow oily compound Rf = 0.27 (1/6 EtOAc / 
(50/70) petroleum ether). Purification was achieved by column chromatography, 
eluting with gradient of (50/70) Petroleum ether) to 1/1 EtOAc / (50/70) petroleum 
ether) to give an oily yellow compound 3.17 (1.25g, 4.8mmol, 21%):  
1H NMR (500 MHz) (CDCl3) δ 5.64 (ddd, 1H, J=5.5Hz, J=10.7Hz, J=21.9Hz, 
CH=CH2), 5.37 (d, 1H, J=8.6Hz, NH), 5.01 (dd, 2H, J=13.6Hz, J=34.6Hz, CH=CH2), 
4.23 (m, 1H, α CH), 3.78 (t, 2H, J=6.2Hz, OCH2), 3.65 (dd, 1H, J=3.2Hz, J=9.4Hz, 
CH2O), 3.55 (s, 3H, OCH3), 3.46 (dd, 1H, J=3.4Hz, J=9.5Hz, CH2O), 1.26 (s, 9H, 
C(CH3)3);  
13C NMR (75 MHz) (CDCl3) δ 170.8, 155.2, 133.9, 116.9, 79.4, 71.8, 69.6, 53.7, 
52.0, 28.0;  
LRMS [ES+ M + [H+] Calcd for C12H21NO5 260.3 found 260.3]. 
 
Synthesis of N-Boc-O-allyl-Ser-OH (3.18) 
 
H
N
O
OHO
O O
3.18
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N-Boc-O-allyl-Ser-OMe 3.17 (0.9g, 3.48mmol) was hydrolysed according to general 
procedure C gave clear oily compound 3.18 (0.7g, 2.85mmol, 82%):  
1H NMR (500 MHz) (CDCl3) δ 5.79 (qd, 1H, J=5.5Hz, J=10.6Hz, CH=CH2), 5.47 (d, 
1H, J=8.5Hz, NH), 5.16 (dd, 2H, J=13.8Hz, J=36.6Hz, CH=CH2), 4.42 (m, 1H, α 
CH), 3.95 (d, 2H, J=5.3Hz, OCH2), 3.85 (dd, 1H, J=2.3Hz, J=9.4Hz, CH2O) 3.63 (dd,  
1H, J=3.3Hz, J=9.6Hz, CH2O), 1.39 (s, 9H, C(CH3)3);  
13C NMR (75 MHz) (CDCl3) δ 174.8, 155.6, 133.9, 117.4, 80.2, 72.2, 69.6, 53.7, 
28.2;  
LRMS [ES+ M + [H+] Calcd for C11H19NO5 246.2 found 246.1]. 
 
Synthesis of N-Boc-O-allyl-Ser-Val-OMe (3.19) 
 
H
N
O
N
H
O
O O
O
O
3.19
 
 
N-Boc-O-allyl-Ser-OH 3.18 (0.63g, 2.57mmol) was coupled to (S)-Val-OMe.HCl 
(0.86g, 5.14mmol) using general procedure A gave crude oily compound Rf = 0.25 
(1/3 EtOAc / (50/70) petroleum ether). Purification was achieved by column 
chromatography, eluting with gradient of (50/70) Petroleum ether) to 100% EtOAc to 
give white solid compound 3.19 (0.67, 1.87mmol, 73%):  
1H NMR (500 MHz) (CDCl3) δ 7.06 (d, 1H, J=5.6Hz, Val (NH)), 5.69 (m, 1H, 
CH=CH2), 5.50 (d, 1H, J=5.6Hz, Ser (NH)), 5.03 (dd, 2H, J=13.1Hz, J=48.6Hz, 
CH=CH2), 4.35 (m, 1H , Ser α CH), 4.14 (s, 1H, Val α CH), 3.84 (d, 2H, J=4.4Hz, 
OCH2), 3.64 (dd, 1H, J=4.3Hz, J=9.3Hz, CH2O), 3.53 (s, 3H, OCH3), 3.39 (dd, 1H, 
J=10.6Hz, J=17.0Hz,  CH2O), 1.98 (m, 1H, Val (CH)), 1.27 (s, 9H, C(CH3)3), 0.73 
(m, 6H, Val (CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 171.7, 170.2, 155.5, 133.9, 117.1, 79.8, 71.9, 69.5, 
56.9, 53.7, 51.7, 30.9 28.0, 18.7, 17.4;  
LRMS [ES+ M + [H+] Calcd for C17H30N2O6 359.4 found 359.3]. 
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Synthesis of N-Boc-O-allyl-Ser-Val-OH (3.20) 
 
H
N
O
N
H
O
O O
OH
O
3.20
 
 
N-Boc-O-allyl-Ser-Val-OMe (0.89g, 2.48mmol) was hydrolysed by general procedure 
C gave compound 3.20 (0.61g, 1.77mmol, 71%): 
1H NMR (500 MHz) (CDCl3) δ 7.01 (d, 1H, J=5.0Hz, Val (NH)), 5.83 (tt, 1H, 
J=5.4Hz, J=15.7Hz, CH=CH2), 5.60 (d, 1H, J=38.8Hz Ser (NH)), 5.20 (dd, 2H, 
J=13.1Hz, J=41.5Hz, CH=CH2), 4.56 (m, 1H, Val α CH), 4.35 (d, 1H, J=34.9Hz, Ser 
α CH),  3.99 (d, 2H, J=4.3Hz, CH2), 3.79-3.53 (m, 2H, CH2O), 2.22 (m, 1H, Val 
CH), 1.42 (s, 9H, C(CH3)3), 0.91 (m, 6H, (CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 174.7, 170.6, 155.8, 133.8, 117.6, 80.2, 72.2, 69.5, 
57.1, 56.9, 31.0, 28.2, 18.9, 17.4;  
LRMS [ES+ M + [H+] Calcd for C16H28N2O6 345.4 found 345.3]. 
 
Synthesis of N-Boc-O-allyl-Ser-Val-S-allyl-Cys-OMe (3.21) 
 
H
N
O
N
H
O
O O
H
N
O
O
O
S
3.21
 
 
N-Boc-O-allyl-Ser-Val-OH 3.20 (0.61g, 1.77mmol) was coupled to (S)-allyl-Cys-
OMe 3.35 (0.62g, 3.54mmol) following general procedure A gave oily orange 
compound Rf = 0.5 (1/1 EtOAc / (50/70) petroleum ether). Purification was achieved 
by flash column chromatography, eluting with gradient of (50/70) Petroleum ether) to 
100% EtOAc to give white solid compound 3.21 (0.48, 0.96mmol, 54%): 
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1H NMR (500 MHz) (CD3OD) δ 5.88 (m, 1H, Ser CH=CH2), 5.75 (qd, 1H, J=7.1Hz, 
J=10.0Hz, Cys CH=CH2), 5.15-5.23(m, 4H, 2(CH=CH2)), 4.60 (m, 1H, Cys α CH), 
4.32 (m, 2H, (Val α CH), (Ser α CH)), 4.00 (t, 2H, J=6.1Hz, OCH2), 3.71 (s, 3H, 
OCH3), 3.65 (m, 2H, CH2O), 3.14 (d, 2H, J=5.0Hz, SCH2), 2.93-2.77 (m, 2H CH2S), 
2.11 (td, 1H, J=6.3Hz, J=13.6Hz, Val CH), 1.44 (s, 9H, C(CH3)3), 0.95 (m, 6H, 
(CH3)2); 
13C NMR (75 MHz) (CD3OD) δ 171.8, 171.4, 171.0, 155.5, 134.3, 133.9, 116.8, 
116.4, 79.9, 71.8, 69.4, 58.2, 55.0, 52.1, 51.6, 34.3, 34.3, 31.2, 27.4, 18.5, 18.4; 
LRMS [ES+ M + [H+] Calcd for C23H39N3O7 S 502.4 found 502.3]. 
 
Synthesis of N-Glu-OMe (3.23) 
 
H2N O
OHO
O
3.23
 
 
L-Glu-(OtBu)-OMe (1.0g, 4.8mmol) was dissolved in 2M HCl in diethyl ether 
(20mL). The resulting solution was leaved to stir at room temperature for 15hr. The 
solvent was removed in vacuo to give white crude product compound (0.8g, 
4.73mmol, 98%):   
1H NMR (300 MHz) (CD3OD) δ 4.05 (t, 1H, J= 5.8Hz, α CH), 3.75 (s, 3H, OCH3), 
2.4 (m, 2H, CH2), 1.98 (m, 2H, CH2) 
 
Synthesis of N-O-allyl-Glu-O-allyl (3.25) 
 
H2N O
O
OO
3.25
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To a stirring solution of compound 3.23 (0.76g, 4.76mmmol) in benzene (50mL) and 
allyl alcohol (2mL) was added para toluene sulfonic acid (0.9 g, 4.8mmol). The 
mixture was refluxed using Dean-Stark trap for 15h.2 The solvent was removed in 
vacuo and the residue was partition with ethyl acetate (30mL) and 1M NaOH (aq) 
(20mL). The organic phase was washed with brine (2 x 15mL), dried over MgSO4 and 
filtered. The solvent was removed in vacuo to give crude orange compound. 
Purification by flash chromatography over silica gel using EtOAc/ (50/70) petroleum 
ether (2/1) as eluent afforded 3.25 (0.16g, 0.7mmol, 15%): 
1H NMR (300 MHz) (CDCl3) δ 5.85 (m, 2H, 2(CH=CH2)), 5.35 (m, 4H, 
2(CH2=CH)), 4.62 (dd, 4H, J=HZ, OCH2), 3.57, (dd, 1H, J=3.17Hz, J=5.15 Hz, α 
CH), 2.47 (m, 2H, γ CH2), 2.14 (m, 1H, β CH2),  1.94 (m, 1H, β CH2);  
LRMS [ES+ M + [H+] Calcd for C11H17NO4 228.2 found 228.2]. 
 
Synthesis of O-allyl-Glu-OH (3.27) 
 
H2N OH
OO
O
3.27
 
 
To a stirred suspension of L-Glu-OH (5g, 34mmol) in dry ally alcohol (120mL) was 
added dropwised chlorotrimethylsilane (10mL).3 The reaction was leaved to stir under 
nitrogen atmosphere for 15hr. Recrystalization at 0 0C with diethyl ether give white 
precipitate product 3.27 which was collected under suction using Buchner funnel 
(4.8g, 26mmol, 77%); 
1H NMR (500 MHz) (CD3OD) δ 5.95 (ddd, 1H, J=5.7Hz, J=10.9Hz, J=22.1Hz, 
CH=CH2), 5.27 (ddd, 2H, J=1.2Hz, J=13.8Hz, J=11.5Hz, CH2=CH), 4.61 (d, 2H, 
J=5.7Hz, OCH2), 4.05 (t, 1H, J=6.7Hz, α CH), 2.63 (m, 2H, γ CH2 ),  2.21 (m, 2H, β 
CH2);  
13C NMR (75 MHz) (CD3OD) δ 171.9, 170.0, 132.2, 117.2, 65.2, 51.8, 29.2, 25.3; 
LRMS [ES+ M + [H+] Calcd for C8H13NO4 188.2 found 188.2]; mp = 123-130 0C 
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Synthesis of N-Boc-O-allyl-Glu-OH (3.28) 
 
O
H
N
OO
OH
O
O
3.28
 
 
To a stirring solution of compound 3.27 (4.75g, 25.4mmol), di-tert-butyl dicarbonate 
(8.1g, 37.2mmol) in dioxane (30mL) and water (30mL) was added dropwised 
triethylamine (14mL, 96mmol). 3 The solution was leave to stir at rt. for 15h and the 
solvent was removed in vacuo. The residue was partition with ethyl acetate (20mL) 
and 10% citric acid (15mL). The aqueous phase was re-extracted with ethyl acetate (2 
x 20mL). The organic phase was washed with brine (2 x 10mL), dried over MgSO4 
and filtered. The solvent was removed in vacuo to give yellow oily compound 3.28 
(5.8g, 20mmol, 80%):  
1H NMR (500 MHz) (CD3OD) δ 5.83 (ddd, 1H, J=5.8Hz, J=11.0Hz, J=16.3Hz, 
CH=CH2), 5.27 (ddd, 2H, J=1.3Hz, J=13.9Hz, J=11.6Hz, CH2=CH), 4.51 (d, 2H, 
J=5.6Hz, OCH2), 4.12 (t, 1H, J=6.7Hz, α CH), 2.41 (m, 2H, γ CH2), 2.16-1.93 (m, 
2H, β CH2), 1.36 (s, 9H, (CH3)3);  
LRMS [ES+ M + [H+] Calcd for C13H21NO6 288.3 found 288.2].  
 
Synthesis of N-Boc-O-allyl-Glu-Val-OMe (3.29) 
 
O
H
N
OO
N
H
O
O
OO
3.29
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N-Boc-O-allyl-Glu-OH 3.28 (2.0g, 7.0mmol) and (S)-Val-OMe.HCl (2.3g, 
13.7mmol) was coupled via general procedure A. This yields a pale yellow crude 
product Rf = 0.38 (1/2 EtOAc/ (50/70) petroleum ether). Purification was achieved by  
column chromatography, eluting with gradient of 1/3 (EtOAc/ (50/70) petroleum 
ether) to 1/1 (EtOAc/ (50/70) petroleum ether) gave compound 3.29 (1.7g, 4.2mmol, 
62%): 
1H NMR (500 MHz) (CDCl3) δ  6.97 (d, 1H, J=8.0Hz, Val (NH)), 5.80 (ddd, 1H, 
J=5.7Hz, J=10.9Hz, J=22.7Hz, CH=CH2), 5.52 (d, 1H, J=7.8Hz, Glu (NH)), 5.16 
(ddd, 2H, J=1.2Hz, J=13.9Hz, J=11.5Hz, CH=CH2), 4.48 (d, 2H, J=5.7Hz, OCH2), 
4.39 (dd, 1H, J=5.1Hz, J=8.6Hz, α Val (CH)), 4.17 (d, 1H, J=6.3Hz, α Glu (CH)), 
3.62 (s, 3H, OCH3), 2.39 (m, 2H, γ CH2), 2.06 (m, 1H, Val (CH)), 2.06 (m, 1H, β 
CH2), 1.86 (qd, 1H, J=7.6Hz, J=14.8Hz, β CH2), 1.32 (s, 9H, (CH3)3), 0.81 (dd, 6H, 
J=6.9Hz, J=13.6Hz, Val (CH3)2);  
13C-NMR (75 MHz) δ 172.5, 171.7, 170.7, 155.5, 131.9, 117.9, 79.4, 64.9, 57.0, 53.3, 
51.7, 30.6, 30.1, 28.0, 27.4, 18.7, 17.5; 
LRMS [ES+ M + [H+] Calcd for C19H32N2O7 401.4 found 401.3]. 
 
Synthesis of N-Boc-Glu(OH)-Val-OH (3.31) 
 
H
N
N
H
OHO
O
OH
O
O
O
3.31
 
 
N-Boc-O-allyl-Glu-Val-OMe 3.29 (1.27g, 3.17mmol) was hydrolysed according to 
procedure C to give crude white solid product 3.31 (0.87g, 2.4mmol, 76%);  
1H NMR (500 MHz) (CDCl3) δ 7.56 (d, 1H, J=8.4Hz, Val (NH)), 5.79 (d, 1H, 
J=8.8Hz, Glu (NH)), 4.52 (dd, 1H, J=4.8Hz, J=8.4Hz, α CH), 4.47 (dd, 1H, J=7.7Hz, 
J=15.4Hz, α CH), 2.45 (m, 2H, γ CH2), 2.24 (qd, 1H, J=6.7Hz, J=13.1Hz, Val (CH)), 
2.01-1.91 (m, 2H, β CH2), 1.41 (s, 9H, C(CH3)3), 0.94 (dd, 6H, J=6.7Hz, J=14.0Hz, 
Val(CH3)2);  
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13C NMR (75 MHz) δ 176.6, 174.9, 172.7, 156.2, 80.6, 57.3, 53.1, 30.6, 29.6, 28.2, 
27.3, 18.9, 17.7;  
LRMS [ES+ M + [H+] Calcd for C15H26N2O7 347.4 found 347.2]. 
 
Synthesis of N-Boc-Val-S-allyl-Cys-OMe (3.32) 
 
N
H
O
O H
N
O
O
O
S
3.32
 
 
Compound 3.35 (1.4g, 8mmol) was coupled to (S)-Boc-Val-H.HCl (3.4g, 16mmol) 
following the general procedure A gave pale yellow crude product Rf = 0.30 (1/3 
EtOAC / (50/70) petroleum ether). Purification was achieved was achieved by column 
chromatography, eluting with gradient (50/70) petroleum ether /1:2 (EtOAC / (50/70) 
petroleum ether) give creamy white solid compound 3.32 (2.7g, 7mmol, 88%):  
1H NMR (500 MHz) (CDCl3) δ 6.67 (d, 1H, J=6.7Hz, NH), 5.72 (m, 1H, CH=CH2), 
5.10 (m, 2H, CH2=CH) 4.77 (dd, 1H, J=5.5Hz, J=12.9Hz, α CH), 3.98 (dd, 1H, 
J=5.5Hz, J=6.6Hz, α CH ), 3.75 (s, 3H, OCH3), 3.10 (m, 2H, SCH2), 2.91 (ddd, 1H, 
J=5.4Hz, J=14.0Hz, J=32.1Hz, CH2S), 2.14 (dd, 1H, J=6.8Hz, J=13.1Hz, Val (CH)), 
1.44 (s, 9H, (CH3)3),  0.95 (dd, 6H, J=6.8Hz, J=22.1Hz, Val(CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 171.4, 170.9, 155.7, 133.5, 117.9, 79.8, 59.5, 52.5, 
51.5, 35.0, 32.3, 30.9, 28.2, 19.1, 17.6;  
LRMS [ES+ M + [H+] Calcd for C17H30N2O5S 375.5 found 375.3]. 
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Synthesis of H-Val-S-allyl-OMe (3.33) 
 
H
NH2N
O
O
O
S
3.33
 
 
N-Boc-Val-S-allyl-Cys-OMe 3.32 (1.1g, 3mmol) was dissolved in 4M HCl in dioxane 
(20mL) and the resulting solution was leaved to stir for 18h at room temperature. The  
solvent was removed in vacuo to yield crude compound 3.33 (0.8g, 2.9mmol, 97%); 
1H NMR (500 MHz (CD3OD) δ 5.79 (tdd, 1H, J=7.2Hz, J=10.0Hz, J=17.1Hz, 
CH=CH2), 5.14 (m, 2H, 2H, CH2=CH), 4.63 (dd, 1H, J=5.1Hz, J=8.6Hz, α CH), 3.76 
(d, 1H, J=5.4Hz, α CH),3.73 (s, 3H, OCH3), 3.18 (m, 2H, SCH2), 2.99 (dd, 1H, 
J=5.1Hz, J=13.9Hz, β CH2), 2.81 (dd, 1H, J=8.6Hz, J=13.9Hz, β CH2), 2.23 (m, 1H, 
Val (CH)), 1.08 (m, 6H, Val (CH3)2);  
LRMS [ES+ M + [H+] Calcd for C12H22N2O3S 275.1 found 275.1]. 
 
Synthesis of N-Boc-O-allyl-Glu-Val-S-allyl-Cys-OMe (3.34) 
 
O
H
N N
HO
O H
N
O
O
O
S
OO
3.34
 
 
H-Val-S-allyl-OMe 3.33 (0.8g, 2.9mmol) was coupled to N-Boc-O-allyl-Glu-OH 3.28 
(0.4g, 1.4mmol) by the coupling general procedure A to give a crude yellow product 
Rf = 0.29 (1/1 EtOAC/- (50/70) petroleum ether). Purification was achieved by 
column chromatography, eluting with gradient 1/3 (EtOAC/- (50/70) petroleum ether) 
to 1/2 (EtOAC/- (50/70) petroleum ether) gave creamy white solid compound 3.34 
(0.60g, 1.2mmol, 38%):  
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1H -NMR (500 MHz) (CDCl3) δ 6.97 (d, 1H, J=7.3Hz, Cys (NH)), 6.91 (d, 1H, 
J=8.2Hz, Val (NH)), 5.89 (m, 1H, Glu (CH=CH2)), 5.72 (m, 1H, Cys (CH=CH2)), 
5.42 (d, 1H, J=7.9Hz, Glu (NH)),5.28 (ddd, 2H, J=5.9Hz, J=18.6Hz, J=35.9Hz, Glu 
(CH2=CH)), 5.09 (dd, 2H, J=5.8Hz, J=10.3Hz, Cys (CH2=CH)), 4.74 (m, 1H, α CH), 
4.57 (d, 1H J=5.7Hz, OCH2), 4.35 (m, 1H, α CH), 4.19 (d, 1H, J=5.8Hz, α CH), 3.73 
(s, 3H, OCH3), 3.09 (m, 2H, SCH2), 2.87 (ddd, 2H, J=5.5Hz, J=13.9Hz, J=20.1Hz, 
CH2S), 2.47 (m, 2H, γ CH2), 2.14 (m, 1H, Val (CH)), 2.14 (m, 1H, β CH2),  1.94 (dt, 
1H, J=7.2Hz, J=14.5Hz, β CH2), 1.41 (s, 9H, (CH3)3), 0.91 (m,6H, Val (CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 173.4, 171.6, 170.9, 170.7, 155.7, 133.5, 131.6, 118.5, 
117.9, 80.1, 65.4, 58.3, 53.2, 52.5, 51.4, 34.9, 32.3, 30.7, 30.5, 28.2, 27.8, 19.1, 17.6; 
LRMS [ES+ M + [H+] Calcd for C25H41N3O8S 544.6 found 544.3].  
 
Synthesis of S-allyl-Cys-OMe (3.35) 
 
H2N O
S
O
3.35
 
 
Compound 3.11 (3.5g, 0.012mol) was dissolved in 4M HCl in dioxane (25mL). The 
reaction was leaved to stir at room temperature for 16h. The solution was then 
concentrated in vacuo to yield white solid. This white solid was dissolved in MeOH 
(30mL) at 0 0C and was added dropwised thionyl chloride (3mL). The resulting 
solution was leaved to stir at room temperature for 20h.  The solvent was removed in 
vacuo to give pale yellow compound 3.35 (1.7g, 0.097mol, 79%):  
1H NMR (500 MHz) (CD3OD) δ 5.81 (tdd, 1H, J=7.2Hz, J=10.0Hz, J=17.1Hz, 
CH=CH2), 5.19 (dd, 2H, J=13.5Hz, J=17.0Hz, CH2=CH), 4.27 (dd, 1H, J=4.4Hz, 
J=7.8Hz, α CH), 3.85 (s, 3H, OCH3), 3.22 (m, 2H, SCH2), 3.10 (dd, 1H, J=4.5Hz, 
J=14.8Hz, β CH), 2.94 (dd, 1H, J=8.0Hz, J=14.8Hz, β CH);  
13C NMR (75 MHz) (CD3OD) δ 168.3, 133.3, 117.4, 52.6, 51.9, 34.1, 29.9;  
LRMS [ES+ M +[H+] Calcd for C7H13NO2S 176.2 found 176.1] 
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Synthesis of N-Boc-Glu-OMe (3.39) 
 
O
H
N
O
O
O
OHO
3.39
 
 
L-H-Glu-OMe (2.7g, 17mmol) and di-tert-butyl dicarbonate (4.4g, 20mmol) were 
dissolved in dioxane (25mL) and water (25mL). Triethylamine (6mL) was added 
dropwised and the solution was leaved to stir at room temperature for 15h. The 
solution was evaporated under reduced pressure. The residue was partition between 
EtOAc (50mL) and 10% citric acid (25mL). The aqueous phase was re-extracted with 
EtOAc (2 x 20mL). All the organic phases were combined, washed with brine (2 x 
15mL), dried over MgSO4 and the solvent was removed in vacuo to give clear oily 
compound 3.39 (3.5 g, 13.4mmol, 79% ): 
1H NMR (500 MHz) (CD3OD) δ  4.27 (dt, 1H, J=4.8Hz, J=8.6Hz, α CH), 3.72 (s, 3H, 
OCH3), 2.35 (t, 2H, J=7.4Hz, γ CH2) , 2.11 (td, 1H, J=6.8Hz, J=12.6Hz, β CH2) 1.89 
(td, 1H, J=8.0Hz, J=22.7Hz, β CH2), 1.42 (s, 9H, C(CH3)3);  
13C NMR (75 MHz) (CDCl3) δ 174.2, 173.4, 155.0, 80.1, 52.8, 51.8, 30.1, 28.2, 27.5; 
LRMS [ES+ M + [H+] Calcd for C11H19NO6 262.3 found 262.2] 
 
Synthesis of N-Boc-N-allyl-Gln-OMe (3.40) 
 
O
H
N
O
O
O
N
H
O
3.40
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N-Boc-Glu-OMe 3.39 (4.2g, 16mmol) was coupled to ally amine (2.03g, 35.6mmol) 
according to general procedure B to give an oily yellow residue crude product Rf = 
0.45 (2/1EtOAc-(50/70) petroleum ether). Purification was achieved using flash 
chromatography, eluting with a gradient of 1/1 (EtOAc / (50/70) petroleum ether to 
100% (EtOAc) to yield purify compound 3.40 (2.64g, 8.8mmol, 55%);  1H NMR (500 
MHz) (CDCl3) δ 6.18 (s, 1H, NH), 5.82 (ddd, 1H, J=5.4Hz, J=10.6Hz, J=16.5Hz, 
CH=CH2), 5.34 (d, 1H, J=6.4Hz, Boc(NH)), 5.14 (dd, 2H, J=13.7Hz, J=33.2Hz 
CH=CH2), 4.27 (dt, 1H, J=4.8Hz, J=8.6Hz, α CH), 3.86 (t, 2H, J=4.7Hz, CONHCH2), 
3.72 (s, 3H, OCH3), 2.30 (t, 2H, J=7.4Hz, γ CH2) , 2.11 (td, 1H, J=6.8Hz, J=12.6Hz, 
β CH2) 1.89 (td, 1H, J=8.0Hz, J=22.7Hz, β CH2), 1.42 (s, 9H, C(CH3)3);  
13C NMR (75 MHz) (CDCl3) δ 172.7, 171.1, 155.7, 134.1, 116.2, 79.9, 60.3, 53.0, 
52.33, 41.9, 32.4, 28.2;  
LRMS [ES M [H+] Calcd for C14H24N2O5 301.3 found 301.2.] 
 
Synthesis of N-Boc-N-ally-Gln-OH (3.41) 
 
O
H
N
O
OH
O
N
H
O
3.41
 
 
N-Boc-N-allyl-Gln-OMe 3.40 (3.31g, 10.5mol) was hydrolysed using general 
procedure C gave a clear oily crude compound 3.41 (2.2g, 7.7mmol, 73%):  
1H NMR (500 MHz) (DMSO) δ 7.94 (t, 1H, J=5.3Hz, NH), 7.05 (d, 1H, J=8.0Hz, Boc 
(NH)), 5.75 (ddd, 1H, J=5.0Hz, J=10.2Hz, J=15.9Hz, CH=CH2), 5.07 (dd, 2H, 
J=13.6Hz, J=34.9Hz, CH=CH2), 3.83 (dt, 1H, J=4.8Hz, J=8.6Hz, α CH), 3.65 (t, 2H, 
J=5.0Hz,  CONHCH2), 2.18 (t, 2H, J=7.6Hz, γ CH2), 1.89(m, 1H, β CH2), 1.71 (dt, 
1H, J=7.4Hz, J=16.1Hz, β CH2), 1.36 (s, 9H, C(CH3)3));  
13C NMR (75 MHz) (DMSO) δ 173.9, 171.3, 155.7, 135.4, 114.9, 78.0, 59.8, 53.1, 
31.7, 28.2, 26.7;  
LRMS [ES M + [H+] Calcd for C13H22N2O5 287.3 found 287.2]. 
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Synthesis of N-Boc-allyl-Gln-Val-OMe (3.42) 
 
O
H
N
O
N
H
O
N
H
O
3.42
O
O
 
 
N-Boc-ally-Gln-OH 3.41 (1.1g, 3.85mmol) was coupled to Val(OMe).HCl (1.3g, 
7.7mmol) according to general procedure A gave white solid crude product Rf = 0.27 
(2/1EtOAc-(50/70) petroleum ether). Purification was achieved using flash 
chromatography, eluting with a gradient of 1/1 (EtOAc / (50/70) petroleum ether to 
100% EtOAc) to yield purified compound 3.42 (0.8g, 2mmol, 52%):  
1H NMR (500 MHz) (DMSO) δ  7.95 (d, 1H, J=5.7Hz, Val (NH)), 7.93 (d, 1H, 
J=6.7Hz, NH), 6.88 (d, 1H, J=8.2Hz, BOC (NH)),  5.76 (ddd, 1H, J=5.2Hz, 
J=10.4Hz, J=22.3Hz, CH=CH2), 5.05 (ddd, 2H, J=1.5Hz, J=13.7Hz, J=11.6Hz, 
CH=CH2 ), 4.17 (dd, 1H, J=6.3Hz, J=8.1Hz, α Val (CH)), 4.02 (t, 1H, J=7.1Hz, α Gln 
(CH)), 3.65 (t, 2H, J=5.4 CONHCH2), 3.61 (s, 3H, OCH3), 2.15 (m, 2H, γ CH2 ), 2.02 
(m, 1H,  Val (CH)), 1.83-1.67 (m, 2H, β CH2), 1.35 (s, 9H, C(CH3)3)), 0.83 (m, 6H, 
Val(CH3)2);  
13C NMR (75 MHz) (DMSO) δ 172.2, 171.9, 171.5, 155.3, 135.4, 114.9, 78.1, 59.8, 
57.2, 53.9, 51.8, 40.8, 31.8, 30.1, 28.2, 18.9, 18.1;  
LRMS [ES M+ [H+] Calcd for C19H33N3O6  400.4 found 400.3]. 
 
Synthesis of N-Boc-N-allyl-Gln-Val-OH (3.43) 
 
O
H
N
O
N
H
O
N
H
O
3.43
OH
O
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N-Boc-N-allyl-Gln-OMe 3.42 (2.2g, 5.6mol) was hydrolysed according to general 
procedure C to give a clear oily compound 3.37 (1.5g, 3.9mmol, 70%):  
1H NMR (500 MHz) (CD3OD) δ 5.83 (ddd, 1H, J=5.5Hz, J=10.6Hz, J=22.5Hz, 
CH=CH2), 5.13 (ddd, 2H, J=1.4Hz, J=13.7Hz, J=11.6Hz, CH=CH2), 4.33 (d, 1H, 
J=5.3Hz, α  Val (CH)), 4.10 (m, 1H, α Gln (CH)), 3.79 (d, 2H, J=1.2Hz, CONHCH2), 
2.33 (t, 2H, J=7.2Hz, γ CH2), 2.19 (m, 1H, Val(CH)), 2.06 (dt, 1H, J=7.0Hz, 
J=13.9Hz, β CH2), 1.87 (dt, 1H, J=7.9Hz, J=15.5Hz, β CH2), 1.43 ( s, 9H, C(CH3)3),  
0.97 (m, 6H, Val(CH3)2);  
13C NMR (75 MHz) (CD3OD) δ 173.5, 173.3, 170.1, 156.4, 134.1, 114.9, 79.3, 57.5, 
53.9, 41.4, 31.8, 30.5, 27.8,  27.3, 18.2, 16.8;  
LRMS [ES M+ [H+] Calcd for C18H31N3O6  386.4 found 386.3]. 
 
Synthesis of N-Boc-allyl-Gln-Val-ally-Gly-OMe (3.44) 
 
O
H
N
O
N
H
O
N
H
O
3.44
H
N
O
O
O
 
 
N-Boc-N-ally-Gln-Val-allyl-Gly-OME 3.43 (0.26g, 0.68mmol) was coupled with (S)-
allyl-Gly-OMe 3.46(0.17g, 1.35mmol) following general procedure A gave pale red 
residue Rf = 0.5 (100% EtOAc). Purification was achieved using flash 
chromatography, eluting with a gradient of 1/1 (EtOAc / (50/70) petroleum ether to 
100% (EtOAc) to yield white solid compound 3.44 (0.1g, 0.20mmol, 30%):  
1H NMR (500 MHz) (CD3OD) δ 5.80 (m, 2H, CH=CH2), 5.12 (m, 2H, CH=CH2), 
4.45 (m, 1H, α Gly (CH)), 4.24 (m, 1H, α Val (CH)), 4.07 (dd, 1H, J=4.5Hz, J=8.9Hz, 
α Gln (CH)), 3.79 (t, 2H, J=4.5Hz, CONHCH2), 3.69 (s, 3H, OCH3), 2.53 (m, 2H, 
Gly (CH2)), 2.29 (t, 2H, J=7.6Hz, β Gln CH2)), 2.03 (m, 2H, Val (CH), β Gln (CH)), 
1.86 (m, 1H, β Gln (CH)), 1.43 (s, 9H, C(CH3)3), 0.95 (m, 6H, Val(CH3)2));  
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13C NMR (75 MHz) (CD3OD) 173.5, 172.7, 171.8, 171.4, 156.7, 133.6, 132.1, 117.9, 
114.5, 79.8, 58.2, 53.9, 52.8, 51.7, 41.3, 35.5, 31.9, 31.2, 27.9, 27.2, 18.2, 17.3; 
LRMS [ES M+ [H+] Calcd for C24H40N4O7  497.6 found 496.4]. 
 
Synthesis of ally-Gly-OMe (3.46) 
 
3.46
ClH.H2N O
O
 
 
(S)-allyl-Gly-OH  (1.00g, 8.69 mmol) was suspended in methanol (30 mL). This was 
cooled to 0oC and SOCl2 (5.0 mL) was added portionwise. The solution was stirred at  
0oC for 1hour and then at room temperature for 18 hours before being concentrated 
in-vacuo to yield a white solid compound 3.40 1.36g,8.24mmol, 95%):  
1H NMR (500 MHz) (CD3OD) δ 5.78 (dddd, 1H J=7.2Hz, J=7.2Hz, J=7.1Hz, 
J=10.0Hz, CH=CH2), 5.28 (dd, 2H, J=13.1Hz, J=13.1Hz, CH=CH2), 4.16 4.15 (dd, 
1H, J=5.4Hz, J=7.0Hz, α CH), 3.84 (s, 3H, OCH3), 2.68 (m, 2H, CH2);  
13C NMR (75 MHz) (CD3OD) δ 169.1, 130.3, 120.3, 52.1, 47.1, 34.4; 
LRMS [ES M+ [H+] Calcd for C6H11NO2 130.2 found 130.1]. 
 
Synthesis of N-Cbz-N-allyl-Gln-OMe (3.48) 
 
O
H
N
O
O
O
N
H
O
3.48
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N-Cbz-Glu-OMe (5.0g, 17mmol), was coupled to ally amine (1.94g, 34mmol) 
following general method B to give clear oily crude compound Rf = 0.32 (2/1 (EtOAc 
/ (50/70) Petroleum ether)).  Purification was achieved by column chromatography, 
eluting with gradient (50/70) petroleum ether)-100% EtOAc to give white solid 
compound 3.48 (5g, 15mmol, 88%):  
1H NMR (500 MHz) (CD3OD) δ 7.31 (m, 5H, Ar,) 5.80 (ddd, 1H, J=5.5Hz, 
J=10.6Hz, J=22.4Hz, CH=CH2),  5.12 (m, 4H, CH2=CH, Z- CH2 ), 4.20 (dd, 1H, 
J=5.0Hz, J=9.2Hz, α CH), 3.77 (d, 2H, J=4.7Hz, CONHCH2),  3.70 (s, 3H, OCH3), 
2.31 (t, 2H, J=7.5Hz, γ CH2), 2.15 (td, 1H, J=7.6Hz, J=13.0Hz, β CH2), 1.93 (ddd, 
1H, J=7.4Hz, J=14.5Hz, J=16.3Hz, β CH2);  
13C NMR (75 MHz) (CD3OD) δ 173.1, 172.7, 157.2, 136.7, 134.1, 128.1, 127.7, 
127.4, 117.2, 66.3, 53.6, 51.2, 41.2, 31.7, 27.1;  
LRMS [ES+ M + [H+] Calcd for C17H22N2O5  335.4 found 335.3]. 
 
Synthesis of N-Cbz-N-allyl-Gln-OH (3.49) 
 
O
H
N
O
OH
O
N
H
O
3.49
 
 
N-Cbz-N-allyl-Gln-OMe 3.48 (5g, 15mmol) was hydrolysed following the general 
procedure C to give oily yellow compound 3.49 (3.7g, 11.4mmol, 76%):  
1H NMR (500 MHz) (CD3OD) δ 7.31 (m, 5H, Ar,)  5.80 (ddd, 1H, J=5.5Hz, 
J=10.6Hz, J=22.4Hz, CH=CH2),  5.12 (m, 4H, CH2=CH, Z- CH2 ), 4.20 (m, 1H, α 
CH), 3.77 (d, 2H, J=4.7Hz, CONHCH2), 2.31 (t, 2H, J=7.5Hz, γ CH2), 2.15 (m, 1H, β 
CH2), 1.93 (m, 1H, β CH2);  
13C NMR (75 MHz) (CD3OD) δ 172.3, 171.6, 155.6, 135.1, 132.4, 126.4, 126.3, 
126.0, 115.6, 64.6, 51.9, 39.2, 30.2, 25.7; LRMS [ES+ M + [H+] Calcd for 
C16H20N2O5 321.3 found 321.2] 
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Synthesis of N-Cbz-N-allyl-Gln-Val-OMe (3.50) 
 
O
H
N
O
N
H
N
H
O
O
O
O
3.50
 
 
N-Cbz-N-allyl-Gln-OH 3.49 (3.66g, 11.4mmol) was coupled to (S)-Val-OMe.HCl 
(3.83g, 23mmol) according to the general procedure A method gave crude product Rf 
= 0.43. Purification was achieved by column chromatography, eluting with gradient 
1/3 (ethyl acetate/ (50/70) petroleum ether) – 2/1 (ethyl acetate/ (50/70) petroleum 
ether) over 16min to give compound 3.50 (4g, 9.2mmol, 80%):  
1H NMR (500 MHz) (CD3OD) δ 7.31 (tdd, 5H, J=6.84Hz, J=9.28Hz, J=6.35, Ar), 
5.80 (ddd, 1H, J=5.38Hz, J=10.6Hz, J=16.4Hz, CH=CH2),  5.12 (m, 4H, CH2=CH, Z-
CH2 ), 4.35 (m, 1H, Val α CH), 4.23 (dd, 1H, J=5.86Hz, J=8.31Hz, Gln α CH ), 4.0-
3.77 (m, 3H, CONHCH2,OCH3), 2.56 (m, 2H, γ CH2), 2.2-2 (m, 2H, Val (CH), β 
CH2), 1.93 (m, 1H, β CH2);  
13C NMR (75 MHz) (CD3OD) δ 173.4, 173.2, 172.3, 157.3, 136.0, 134.0, 128.2, 
127.7, 127.5, 117.1, 66.4, 57.9, 54.3, 51.3, 41.5, 31.6, 30.4, 27.9, 18.1, 17.3; 
LRMS [ES+ M + [H+] Calcd for C22H31N3O6 434.5 found 434.3] 
 
Synthesis of N-Cbz-N-allyl-Gln-Val-OH (3.51) 
 
O
H
N
O
N
H
N
H
O
O
OH
O
3.51
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N-Cbz-N-allyl-Gln-Val-OMe 3.51 (4g, 9.2mmol) was hydrolysed according to 
general procedure C to give a white solid compound 3.51 (1.6g, 3.8mmol, 41%):  
1H NMR (500 MHz) (CD3OD) δ 7.31 (m, 5H, Ar), 5.80 (ddd, 1H, J=5.5Hz, 
J=10.6Hz, J=22.4Hz, CH=CH2),  5.12 (m, 4H, CH2=CH, Z-CH2 ), 4.35 (m, 1H, Val α 
CH), 4.20 (dd, 1H, J=5.0Hz, J=9.2Hz, Gln α CH), 3.77 (d, 2H, CONHCH2), 2.31 (t, 
2H, J=7.5Hz, γ CH2), 2.20 (m, 1H, Val (CH)), 2.15-1.93 (m, 2H, β CH2), 0.91 (m, 
6H, Val (CH3)2);  
13C NMR (75 MHz) (CD3OD) δ 177.3, 177.2, 176.7, 161.4, 140.1, 137.6, 132.2, 
131.7, 131.5, 119.5, 70.6, 61.6, 61.5, 45.5, 35.8, 34.2, 32.2, 22.3, 20.9;  
LRMS [ES+ M + [H+] Calcd for C21H29N3O6  420.5 found 420.3]. 
 
Synthesis of N-Cbz-N-allyl-Gln-Val- allyl-Gly -OMe (3.52) 
 
O
H
N
O
N
H
N
H
O
O H
N
O
O
O
3.52
 
 
To a stirring solution of N-Cbz-N-allyl-Gln-Val-OH 3.51 (1.53g, 3.65mmol), (S)-
allyl-Gly-OMe 3.46 (1.2g, 7.3mmol) and HATU (1.53g, 4.0mmol) in DMF (30mL) 
was added DIPEA (2.5mL, 14.6mmol). The orange solution was leaved to stir at room 
temperature for 15h before being partition with EtOAC and 1M HCl(aq). The partition 
resulted in a white solid formation between the two layers which was collected using 
Buchner funnel gave compound 3.52 (1.6g, 3.0mmol, 83% yield):  
1H NMR (500 MHz) (DMSO) δ 7.31 (m, 5H, Ar), 5.80 (m, 2H, J=5.5Hz, J=10.6Hz, 
J=22.4Hz, 2(CH=CH2)),  5.12 (m, 6H, 2(CH2=CH), Z-CH2 ), 4.37 (m, 1H, Gly α 
CH), 4.20 (t, 1H, J=5Hz, Gly α CH), 4.02 (dd, 1H, J=5.0Hz, J=9.2Hz, Gln α CH), 
3.62 (d, 2H, CONHCH2), 3.59 (s, 3H, OCH3), 2.39, (m, 2H, Gly (CH2)), 2.18 (m, 
2H,  γ CH2), 1.98 (m, 1H, Val(CH)), 1.89-1.75 (m, 2H, β CH2), 0.91 (m, 6H, Val 
(CH3)2);  
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13C NMR (75 MHz) (DMSO) δ 171.7, 171.5, 171.1, 170.5, 155.9, 136.5, 135.3, 
133.6, 128.4, 127.8, 127.6, 117.9, 114.9, 65.4, 61.6, 57.0, 54.4, 51.9, 51.7, 34.9, 31.9, 
30.9, 28.1, 19.0, 17.8;  
LRMS [ES+ M + [H+] Calcd for C27H38N4O7 531.4 found 531.3]. 
 
Synthesis of N-Boc-O-allyl-Tyr-Val-OMe (3.54) 
 
BocHN
N
H
O
O
O
O
3.54
 
 
N-Boc-O-allyl-Tyr (5g, 16.3mmol) was coupled to (s)-Val-OMe.HCl (5.4g, 
32.5mmol) according to general procedure B. The crude product was purified using 
column chromatography Rf value = 0.25 in 1/5 EtOAc/ (50/70) Pet ether, eluting with 
a gradient of (50/70) petroleum ether to 100% EtOAc to yield a white solid compound 
3.54 (2.8g, 6.52mmol, 40%):  
1H NMR (500 in CDCl3) δ 7.09 (2H, d J=6.5Hz, Ar-H), 6.80 (2H, d J=6.4Hz, Ar-H), 
6.47 (1H, bs, Val (NH)), 5.97-6.05 (1H, m, CH=CH2), 5.30 (2H, ddd J=1.1Hz, 
J=13.9Hz, J=11.3Hz, CH=CH2), 5.12 (1H, bs, Tyr (NH)), 4.47-4.49 (2H, m, 
OCH2CH=CH2), 4.43 (1H, dd J=6.3Hz, J=7.3Hz, Tyr α CH), 4.30-4.34 (1H, m, Val α 
(CH)), 3.66 (3H, s, OCH3), 2.98 (2H, d J=3.4Hz, CHCH2Ph), 2.04-2.11 (1H, m, 
CHCH(CH3)2), 1.39 (9H, s, (C(CH3)3)), 0.83 (6H, dd J=6.7Hz, J=14.6Hz, Val 
(CH3)2);  
13C NMR (75 MHz in CDCl3) 174.7, 171.9, 157.5, 133.2, 130.3, 128.6, 117.6, 114.8, 
68.7, 57.2, 37.0, 31.0, 28.2, 18.8, 17.6;  
LRMS [ES+ M + [H+] Calcd for C23H34N2O6 435.3 found 435.3]  
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Synthesis of N-Boc-O-allyl-Tyr-Val-OH (3.55) 
 
BocHN
N
H
O
O
OH
O
3.55
 
 
N-Boc-O-allyl-Tyr-Val-OMe 3.54 (2.5g, 5.75mmol) was hydrolysed using general 
procedure C to give white solid compound 3.55 (1.88g, 4.48mmol, 78%):  
1H NMR (500 MHz) ( CDCl3) δ 7.10 (d, 2H, J=8.4Hz, 2H Ar ), 6.82 (d, 2H, J=8.2Hz, 
2H Ar), 6.70 (d, 1H, J=5.8Hz, NH (Val)), 6.03 (m, 1H, CH=CH2), 5.32 (dd, 2H, 
J=14.3Hz, J=60.7Hz, CH=CH2), 4.97 (d, 1H, J=7.7Hz, NH (Tyr)), 4.56 (d, 1H, 
J=5.8Hz, α CH(Val)), 4.49 (dd, 2H, J=6.8Hz, J=12.3Hz, O-CH2), 4.39 (d, 1H, 
J=4.3Hz,α CH (Tyr)), 3.08 (m, 2H, CH2), 2.19 (qd, 1H, J=6.7Hz, J=13.7Hz, 
CH(Val)), 1.39 (s, 9H, (C(CH3)3)), 0.90 (dd, 6H, J=6.8Hz, J=13.3Hz, Val (CH3)2); 
13C NMR (75MHz) (CDCl3) δ 174.9, 171.8, 157.5, 155.8, 133.2, 130.3, 128.5, 117.5, 
114.7, 80.3, 68.7, 57.1, 55.8, 37.0, 30.9, 28.1, 18.8, 17.5;  
LRMS [ES+ M + [H+] Calcd for C22H32N2O6S 421.4 found 421.3].  
 
Synthesis of N-Boc-O-allyl-Glu-OMe (3.56) 
 
H
N O
O
OO
O
O
3.56
 
 
To a stirred solution of N-Boc-O-allyl-Glu-OH 3.28 (5.8g, 20mmol) in diethyl ether 
(40mL) at 00C was added dropwised excess diazomethane. The solution was leaved to 
stir at 00C for 1h and the excess diazomethane was purges with argon for15-20min. 
The solution was removed in vacuo to give clear oily yellow crude compound Rf = 0.3  
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(1/3 (EtOAc/(50/70) Pet ether)). Purification was achieved using flash 
chromatography, eluting with a gradient of 1/5 (EtOAc/ (50/70) Pet ether to 100% 
(EtOAc) to yield purify compound 3.56 (3.6g, 12mmol, 60%):  
1H NMR (500 MHz) (CDCl3) δ 5.89 (ddd, 1H, J=5.7Hz, J=10.4Hz, J=22.9Hz, 
CH=CH2), 5.26 (ddd, 2H, J=1.3Hz, J=13.8Hz, J=11.6Hz, CH=CH2), 5.12 (d, 1H, 
J=7.6Hz, NH) 4.57 (d, 2H, J=5.8Hz, O-CH2), 4.33 (d, 1H, J=5.1Hz, α CH), 3.73 (s, 
3H, CH3O), 2.42 (m, 2H, γ CH2), 2.18 (dt, 1H, J=7.1Hz, J=13.6Hz, β CH2),1.94 (dt, 
1H, J=8.3Hz, J=14.6Hz, β CH2), 1.42 (s, 9H, C(CH3)3);  
13C NMR (75 MHz) δ 173.0, 172.7, 155.7, 132.4, 118.8, 80.1, 65.7, 53.2, 52.8, 30.6, 
28.6, 28.1;  
LRMS [ES+ M + [H+] Calcd for C14H23NO6 302.3 found 302.1] 
 
Synthesis of O-allyl-Glu-OMe (3.57) 
 
 
H2N O
O
OO
3.57
 
 
 
N-Boc-O-allyl-Glu-OMe 3.56(2.9g, 12mmol) was dissolved in 2M HCl in diethyl 
ether (12mL). The resulting reaction was leaved to stir for 18h and the solvent was 
removed in vacuo to give yellow solid compound 3.57 (2.4g, 12mmol, 100%):  
1H NMR (500 MHz) (DMSO)  δ 8.72 (bs, 2H, NH), 5.89 (ddd, 1H, J=5.5Hz, 
J=10.6Hz, J=22.5Hz, CH=CH2), 5.24 (dd, 2H, J=14.1Hz, J=43.9Hz, CH=CH2), 4.54 
(d, 1H, J=5.4Hz, OCH2), 4.02 (d, 1H, J=4.6Hz, α CH), 3.71 (s, 3H, OCH3), 2.56 (m, 
2H, γ CH2),  2.06 (m, 2H, β CH2);  
13C NMR (75 MHz) δ 171.4, 169.5, 132.6, 117.9, 64.6, 52.8, 51.1, 29.0, 25.1;  
LRMS [ES+ M + [H+] Calcd for C9H15NO4 202.2 found 202.1]. 
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Synthesis of N-Boc-O-allyl-Tyr-Val-O-ally-Glu-OMe (3.58) 
 
H
N
N
H
O H
N
O
O
O
O
O
O
O O
3.58
 
 
N-Boc-O-allyl-Tyr-Val-OH 3.55 (1g, 2.4mmol) was coupled to O-allyl-Glu-OMe 
3.57 (0.9g, 4.6mmol) using general procedure A to give a yellow crude compound Rf 
= 0.5 (1/1 (EtOAc / (50/70) Pet ether). Purification was achieved using flash 
chromatography, eluting with a gradient of 1/3 (EtOAc / (50/70) Pet ether to 100% 
(EtOAc) to yield a white solid compound 3.58 (0.7g, 1.2mmol, 50%): 
1H NMR (500 MHz) (CDCl3) δ 7.10 (d, 2H, J=8.5Hz, CH2 Ar), 6.87 (d, 2H, J=6.8Hz, 
Val (NH)), 6.83 (d, 2H, J=8.5Hz, CH2 Ar), 6.58 (d, 1H, J=8.3Hz, Glu (NH)), 6.03 
(ddd, 1H, J=5.3Hz, J=10.5Hz, J=22.5Hz, Tyr (CH= CH2)), 5.89 (ddd, 1H, J=5.9Hz, 
J=11.2Hz, J=16.3Hz, Glu (CH=CH2)), 5.38 (dd, 2H, J=16.3Hz, J=32.1Hz, Tyr 
(CH=CH2)), 5.24 (dd, 2H, J=10.1Hz, J=23.6Hz, Glu (CH=CH2)), 5.02 (d, 1H, 
J=5.0Hz, Tyr (NH)), 4.57 (d, 2H, J=5.7Hz, Glu (CH2CH=CH2)), 4.53 (d, 1H, 
J=5.2Hz, Glu α (CH)), 4.50 (d, 2H, J=5.3Hz, Tyr (CH2CH=CH2)), 4.32 (d, 1H, 
J=4.5Hz, Tyr α (CH)),  4.25 (dd, 1H, J=6.4Hz, J=8.0Hz, Val  α (CH)), 3.73 (s, 3H, 
OCH3), 3.01 (m, 2H, Tyr β (CH2)), 2.42 (m, 2H, γ CH2), 2.20 (td, 1H, J=7.5Hz, 
J=12.9Hz, β CH2), 2.14 (m, 1H, Val (CH)), 2.02 (dt, 1H, J=7.8Hz, J=14.5Hz, β CH2), 
1.39 (s, 9H, C(CH3)3), 0.88 (dd, 6H, J=6.8Hz, J=17.0Hz, Val (CH3)2);  
13C NMR (75MHz) (CDCl3) δ 172.5, 171.8, 171.4, 170.7, 157.5, 155.7, 133.2, 131.9, 
130.2, 128.5, 118.4, 117.6, 114.7, 80.1, 68.7, 65.4, 58.4, 55.8, 52.4, 51.7, 37.3, 30.7, 
30.1, 28.2, 26.7, 18.9, 17.7;  
LRMS [ES+ M + [H+] Calcd for C31H45N3O9 604.3 found 604.3];  
mp= 83-87 0C. 
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Synthesis of N-Boc-O-allyl-Tyr-Leu-OMe (3.60) 
 
BocHN
N
H
O
O
O
O
3.60
 
 
N-Boc-O-allyl-Tyr-H (18.6g, 60.5mmol), HATU (25.3g, 67mmol) and Leu-OMe 3.59 
(22g, 121mmol) were dissolved in anhydrous DMF (100mL) at 00C. To this DIPEA 
(42.2mL, 242mmol) was added.  The yellow solution was stirred at room temperature, 
for 18h. The reaction mixture was partitioned between ethyl acetate and 1M HCl(aq).  
The organic phase was then washed sequentially with 1M HCl(aq) and brine before 
being dried (MgSO4), filtered and concentrated in vacuo to give yellow crude product 
Rf = 0.33 (1/3 (EtOAc / (50/70) Petroleum ether)). Purification was achieved by flash 
column chromatography. The column was eluting with a gradient of 1/5 (EtOAc/ 
(50/70) Petroleum ether) to 100% EtOAc to give a white solid compound 3.60 (16g, 
35.7mmol, 59%):  
1H NMR (500 MHz) (CDCl3) δ 7.02 (d, 2H, J=8.1 Hz, Ar), 6.77 (d, 1H, J=5.4Hz, 
NH), 6.73 (d, 2H, J=8.0, Ar), 5.94 (dq, 1H, J=4.9Hz, J=10.2Hz, CH=CH2), 5.30 (d, 
2H, J=17.2Hz, CH=CH2 ), 5.17 (d, 1H, J=10.5Hz, NH), 4.49 (m, 1H, Tyr α (CH)), 
4.5 (d, 2H, 4.2 Hz OCH2), 4.34 (d, 1H, J=4.7Hz Leu α (CH)),  3.61(s, 3H, OCH3) 
2.90 (ddd, 2H, J=6.6Hz, J=13.7Hz, J=20.9Hz CH2-Ar), 1.51 (m, 2H, CH2-CH-(CH3)2) 
1.43 (dd, 1H, J=9.2Hz, J=17.7Hz, CH2-CH-(CH3)2), 1.32 (s, 9H, C(CH)3) 0.81 (m, 
6H, Leu (CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 174.1, 172.8, 171.3, 157.3, 155.3, 133.2, 130.3, 128.8, 
117.2, 114.5, 79.6, 68.5, 55.5, 52.0, 50.0, 41.1, 37.3, 28.1, 24.5, 22.6, 21.7;  
LRMS [ES+ M + [H+] Calcd for C24H36N2O6 449.6 found 449.6].  
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Synthesis of O-allyl-Tyr-Leu-OMe (3.61) 
  
H2N N
H
O
O
O
O
3.61
 
 
To N-Boc-O-allyl-Tyr-Leu-OMe 3.60 (15.7g, 35mmol) was added 4M HCl in 1,4-
dioxane (80mL).  This was stirred at room temperature for 16 hours and the solution 
was then concentrated in-vacuo to yield a white solid 3.61 (12.2 g, 100%):  
1H NMR (500 MHz in CDCl3) 8.28 (bs, 2H, NH2),  7.67 (d, 1H, J=6.4Hz Leu NH), 
7.27 (d, 2H, J=8.4Hz, Tyr Ar-H), 6.82 (d, 2H, J=8.4Hz, Tyr Ar-H), 6.00 (ddd, 1H, 
J=5.2Hz, J=10.5Hz, J=22.2Hz, CH=CH2), 5.31 (dd, 2H, J=14.5Hz, J=59.7Hz, 
CH=CH2), 4.60 (1H, m, Tyr α CH), 4.44 (d, 2H, J=5.2Hz, OCH2), 4.32 (m, 1H, Leu 
CH), 3.63 (s, 3H, OCH3), 3.36 (dd, 1H,  J=4.3Hz, J=13.9Hz Tyr CH2), 3.20 (1H, dd 
J=8.2Hz, J=14.0Hz, Tyr CH2), 1.56 (m, 3H, Leu CH2CH and Leu CH2CH), 0.83 (m, 
6H, Leu C(CH3)2);  
13C NMR (75 MHz in CDCl3). 172.4, 168.2, 157.9, 133.1, 131.0, 126.2, 117.5, 114.9, 
68.6, 67.0, 54.6, 52.2, 51.4, 40.1, 36.2, 24.5, 22.5, 21.9;  
LRMS [ES+ M + [H+] Calcd for C19H28N2O4 349.5 found 349.4].  
 
Synthesis of 4-F-Ph-SO2-N-Tyr-O-Allyl-Leu-OMe (3.62)  
 
H
N
O
SF
O
O NH
O
O
O
3.62
 
 
Tyr-O-allyl-Leu-OMe.HCl 3.61 (15.7g, 45mmol) and 4-fluoro-benzene sulfonyl 
chloride (7.97g, 40.9mmol) were dissolved in anhydrous DCM (100mL).  To this  
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DIPEA (15.7mL, 90mmol) was added.  This was stirred at room temperature for 18 
hours before being concentrated in-vacuo.  The residue was then partitioned between 
EtOAC and 1M HCl(aq).  The organic phase was then washed sequentially with 1M 
HCl(aq) and brine before being dried (MgSO4), filtered and concentrated in-vacuo. Rf = 
0.42 (1/2 (EtOAc / (50/70) Petroleum ether)).  Purification was achieved using flash 
chromatography, eluting with gradient of (50/70) Pet ether to 1/1 (EtOAc / (50/70) Pet 
ether to yield a dark yellow compound 3.62 (12.57g, 24.9mmol, 61%):  
1H NMR (500 MHz) (CDCl3) δ 7.69 (2H, dd J=5.0Hz, J=8.9Hz, Ar-H (4-F-Ph)), 7.08 
(2H, t, J=8.6Hz, Ar-H (4-F-Ph)), 6.91 (2H, d J=8.6Hz, Ar-H (Tyr)), 6.73 (2H, d 
J=8.6Hz, Ar-H (Tyr)), 6.42 (1H, d J=8.2Hz, Leu (NH)), 6.05 (1H, ddd J=5.3Hz, 
J=10.6Hz, J=22.6Hz, CH=CH2), 5.45 (1H, d, J=7.93Hz, Tyr (NH)), 5.40 (2H, ddd 
J=15.46Hz, J=46.39Hz, J=10.3Hz, CH=CH2), 4.49 (3H, m, O-CH2, and α CH (Leu)), 
3.86 (1H, dd, J=6.8Hz, J=13.8Hz α CH (Tyr)), 3.71 (3H, s, O-CH3), 2.92 (2H, m, 
CH2 (Tyr)), 1.55 (1H, m,CHCH2 Leu), 1.42 (1H, m,CHCH2Leu), 0.88 (6H, d, 
J=6.2Hz Leu (CH3)2);  
13C NMR (75 MHz) (CDCl3) δ 172.5, 169.9, 166.6, 163.2, 157.7, 135.2, 135.1, 133.0, 
130.2, 129.8, 129.7, 127.2, 117.7, 116.3, 116.0, 114.8, 68.6, 57.9, 52.3, 50.9, 41.3, 
37.7, 24.6, 22.5, 21.8;  
LRMS [ES+ M + [H+] Calcd for C25H31FN2O6S 507.3 found 507.2]  
 
Synthesis of 4-F-Ph-SO2-N-Tyr-O-Allyl-Leu-OH (3.63) 
 
H
N
O
SF
O
O NH
O
OH
O
3.63
 
 
N-4-F-Ph-SO2-O-allyl-Tyr-Leu-OMe 3.62 (11.96, 23.7mmol) was hydrolysed 
according to general procedure B to yield a yellow compound 3.63 (11g, 22.3mmol, 
94%):  
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1H NMR (500 MHz) (CDCl3) δ 7.69 (2H, dd J=4.75Hz, J=8.32Hz, Ar-H (4-F-Ph)), 
7.08 (2H, t, J=8.72Hz, Ar-H (4-F-Ph)), 6.97 (1H, d J=8.32Hz, Leu (NH)),  6.91 (2H, 
d J=8.33Hz, Ar-H (Tyr)), 6.73 (2H, d J=8.33Hz, Ar-H (Tyr)), 6.05 (1H, ddd 
J=5.17Hz, J=10.3Hz, J=15.86Hz, CH=CH2), 5.45 (1H, d, J=7.93Hz, Tyr (NH)), 5.40 
(2H, ddd J=17.05Hz, J=42.82Hz, J=10.7Hz, CH=CH2), 4.45 (1H, dd, J=8.32Hz, 
J=13.5Hz α CH (Leu)), 4.42 (2H, d, J=4.36Hz, OCH2 ),3.95 (1H, dd, J=7.93Hz, 
J=13.48Hz α CH (Tyr)), 3.71 (3H, s, OCH3), 2.92 (2H, m, CH2 (Tyr)), 1.55 (1H, 
m,CHCH2 Leu), 1.42 (1H, m,CHCH2Leu), 0.88 (6H, d, J=6.2Hz Leu (CH3)2 );  
13C NMR (75 MHz) (CDCl3) δ 175.7, 170.9, 166.6, 163.2, 157.7, 135.1, 135.0,133.0, 
130.2, 129.8, 129.7, 127.1, 117.7, 116.3, 116.0, 114.8, 68.6, 58.0, 51.0, 40.8, 37.5, 
24.6, 22.7, 21.6;  
LRMS [ES+ M + [H+] Calcd for C24H29FN2O6S 492.5 found 492.2]. 
 
Synthesis of 4-F-Ph-SO2-N-Tyr-O-Allyl-Leu-Gly-allyl-OMe (3.64) 
 
H
N
O
SF
O
O NH
O
O
H
N O
O
3.64
 
 
4-F-Ph-SO2-N-Tyr-O-Allyl-Leu-H 3.64 (3.3g, 6.6mmol) was coupled with (s)-allyl-
Gly-OMe 3.46 (2.2g, 13mmol) following general procedure A to give a crude orange 
compound Rf = 0.38 (1/1 (EtOAc / (50/70) Pet ether)).  Purification was achieved 
using flash chromatography, eluting with gradient of (50/70) Petroleum ether to 2/1 
(EtOAc / (50/70) Pet ether) to yield a white solid compound 3.64 (3g, 4.96mmol, 
75%):  
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1H NMR (500 MHz) (CDCl3) δ 7.60 (dd, 2H, J=5.0Hz, J=8.3Hz, Ar-H (4-F-Ph)), 7.04 
(t, 2H, J=8.3Hz Ar-H (4-F-Ph)), 6.98 (d, 1H, J=8.0Hz, Gly (NH)), 6.90 (d, 1H, 
J=8.4Hz, Leu (NH)), 6.83 (d, 2H, J=8.3Hz Ar-H (Tyr)), 6.69 (d, 2H, J=8.2Hz, Ar-H 
(Tyr)), 6.04 (ddd, 1H, J=5.7Hz, J=10.6Hz, J=22.4Hz, Tyr CH=CH2), 5.70 (tdd, 1H, 
J=7.2Hz, J=10.0Hz, J=17.1Hz, Gly CH=CH2), 5.41 (d, 1H, J=17.3Hz, Tyr (NH)), 
5.32 (dd, 2H, J=8.3Hz, J=14.7Hz, Tyr CH2=CH), 5.11 (t, 2H, J=12.9Hz, Gly 
CH2=CH), 4.61 (dd, 1H, J=7.4Hz, J=13.1Hz, Gly α CH), 4.46 (m, 3H, m, OCH2, and 
Leu α CH), 3.77 (m, 1H, Tyr α CH), 3.73 (3H, s, OCH3), 3.03 (dd, 1H, J=4.6Hz, 
J=14.3Hz, β CH(Tyr)), 2.70 (dd, 1H, J=9.0Hz, J=14.2Hz, Tyr β CH), 2.52 (2H, m, 
Gly (CH2)), 1.72 (1H, m, Leu CHCH2), 1.49 (2H, m, Leu CHCH2), 0.91 (6H, d, 
J=6.2Hz Leu (CH3)2); );  
13C NMR (75 MHz) (CDCl3) δ 171.7, 171.5, 170.4, 167.3, 163.7, 157.7, 134.4, 134.3, 
133.0, 132.3, 130.2, 129.9, 129.8, 127.2, 118.9, 117.7, 116.3, 116.0, 114.8, 68.6, 58.4, 
52.2, 51.9, 51.9, 41.0, 37.5, 36.1, 24.6, 22.8, 21.9;  
LRMS [ES+ M + [H+] Calcd for C30H38FN3O7S 604.2 found 604.3].  
 
 
6.3 EXPERIMENTAL DESCRIBED FROM CHAPTER 4 
 
 
Synthesis of N-Boc-Cys-Val-Cys-ene-Macrocycle-OMe (4.1) 
 
BocHN
N
H
O H
N
O
CO2Me
S S
4.1
 
 
RCM of N-Boc-S-allyl-Cys-Val-S-ally-Cys-OMe 3.15 (0.94g, 1.8mmol) was carried 
out following general procedure D to give black solid crude product Rf = 0.23 (1/1 
(EtOAc / (50/70) Pet ether)). Purification was achieved using flash chromatography, 
eluting with gradient of (50/70) Petroleum ether to 100% EtOAc to yield a brown 
solid compound 4.1 (0.3g, 0.6mmol, 33%) mixtures of E/Z isomers:  
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1H NMR (500 MHz) (CDCl3) δ 7.30 (d, 1H, J=8.0Hz, NH) 7.17 (d, 1H, J=7.8Hz, 
NH), 7.35 (d, 1H, NH) 7.07 (d, 1H, J=7.0Hz, NH), 6.88 (d, 1H, J=7.4Hz, NH), 
5.71(d, 1H, J=7.6Hz, NH), 5.46 (m, 2H, 2(CH=CH2)), 4.85 (m, 1H, α CH),  4.41 (dd, 
1H, J=7.4Hz, J=15.2Hz, Val α (CH)), 4.28 (m, 1H, α CH), 3.78 (s, 3H, OCH3), 2.8-
3.2 (m, 8H, 2(CH=CH2) and 2(SCH2)), 2.10 (m, 1H, Val CH), 1.43 (s, 9H, C(CH3)3), 
0.96 (m, 6H, C(CH3)2);  
LRMS [ES+ M + [H+] Calcd for C21H35N3O6S2 490.6 found 490.3].  
 
 
Synthesis of N-Boc-Cys-Val-Cys-Macrocycle-OMe (2.5) 
 
BocHN
N
H
O H
N
O
CO2Me
S S
2.5
 
 
N-Boc-S-allyl-Cys-Val-S-ally-Cys-ene-Macrocycle-OMe 4.1 was dissolved in 
methanol (20mL) and dichloromethane (20mL). The solution was de-gas and 10% 
palladium on carbon was added. This was subjected to hydrogenation while stirring 
for 18 hours. The mixture was then filtered through celite and concentrated in vacuo 
to yield brown solid compound 2.5 (0.26g, 0.53mmol, 95%):  
1H NMR (500 MHz) (CDCl3) 7.03 (d, 1H, J=6.2Hz, Cys (NH)), 6.84 (d, 1H, J=7.4Hz, 
Val (NH)), 5.53 (d, 1H, J=6.7Hz, Cys (NH)), 4.88 (m, 1H, Cys α  (CH)), 4.43 (m, 
1H, Val α (CH)), 4.29 (m, 1H, Cys α  (CH)), 3.78 (s, 3H, OCH3), 2.8-3.2 (m, 4H, 
2(CH2S), 2.4-2.6 (m, 4H, SCH2CH2CH2CH2S), 2.15 (m, 1H, Val(CH)), 1.65-1.7 (m, 
4H, SCH2CH2CH2CH2S), 1.45 (s, 9H, C(CH3)3), 0.96 (m, 6H, Val C(CH3)2);  
LRMS [ES+ M + [H+] Calcd for C21H37N3O6S2 492.6 found 492.3.  
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Synthesis of N-Boc-Ser-Val-Cys-ene-Macrocycle-OMe (4.2) 
 
BocHN
N
H
O H
N
O
CO2Me
O S
4.2
 
 
RCM of N-Boc-O-allyl-Ser-Val-S-ally-Cys-OMe 3.21 (0.48g, 0.96mmol) was carried 
out following general procedure D to give black solid crude product Rf = 0.27 (1/1 
(EtOAc / (50/70) Pet ether)). Purification was achieved using flash chromatography, 
eluting with gradient of (50/70) Petroleum ether to 100% EtOAc to yield a brown 
solid compound 4.2 (0.06g, 0.13mmol, 14%) mixtures of E/Z isomers:  
1H-NMR (500 MHz) (CDCl3) δ 6.89 (d, 1H, J=8.2Hz, NH), 6.58 (d, 1H, J=8.8Hz, 
NH), 5.62 (m, 3H, NH, 2(CH=CH2)), 5.46 (m, 1H, (CH=CH2)), 4.73 (m, 1H, α CH), 
4.29 (m, 1H, α CH), 4.20(m, 1H, α CH ), 3.78-3.9 ( m,5H, OCH2 and OCH3), 3.68-
3.75 (m,2H, CH2O), 3.2(m, 2H, SCH2), 2.85 (m, 2H, CH2S), 2.13 (m, 1H, Val(CH)), 
1.45-1.5 (s, 9H, C(CH3)3), 0.96 (m, 6H, Val C(CH3)2);  
LRMS [ES+ M + [H+] Calcd for C21H35N3O7S2 474.6 found 474.5].  
 
Synthesis of N-Boc-Ser-Val-Cys-Macrocycle-OMe (2.6) 
 
BocHN
N
H
O H
N
O
CO2Me
O S
2.6
 
 
N-Boc-O-allyl-Ser-Val-S-ally-Cys-ene-Macrocycle-OMe 4.2 was dissolved in 
methanol (15mL) and dichloromethane (15mL). The solution was de-gas and 10% 
palladium on carbon was added. This was subjected to hydrogenation while stirring 
for 18 hours. The mixture was then filtered through celite and concentrated in vacuo 
to yield brown solid compound 2.6 (0.12mg, 0.24mmol, 53%):  
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1H NMR (500 MHz) (CDCl3) δ 6.86 (d, 1H, J=14.9Hz, NH), 6.56 (d, 1H, J=10.1Hz, 
NH), 5.43 (m, 1H, NH), 4.78 (m, 1H, Cys α CH), 4.5 (m, 1H, Val α CH), 4.02 (m, 
1H, Ser α CH), 3.79 (s, 3H, OCH3), 3.5-3.7 (m, 2H, CH2O), 3.35-3.6 (m, 2H, OCH2), 
2.9-3.2 (m,2H, CH2S), 2.48 (m, 2H, SCH2), 2.08 (m, 1H, Val (CH)), 1.58-1.79 (m, 
4H, OCH2CH2CH2CH2S), 1.45 (s, 9H, C(CH3)3), 0.96 (m, 6H, Val C(CH3)2);  
LRMS [ES+ M + [H+] Calcd for C21H37N3O7S 476.6 found 476.2].  
 
Synthesis of N-Boc-Glu-Val-Cys-ene-Macrocycle-OMe (2.7) 
 
BocHN
N
H
O H
N
O
CO2Me
OO
S
E/Z 2.7
 
 
Compound 3.34 (0.4g, 0.74mmol), (0.2g, 0.37mmol) undergo RCM via general 
procedures F and E respectively Rf = 0.6 (2/1 (EtOAc / (50/70) Petroleum ether)).  
Purification was achieved using flash chromatography, eluting with gradient of 
(50/70) Pet ether to 100% EtOAC to yield brown compound 2.7 (0.19g, 0.37 mmol, 
50% conditions F) and (0.08mg, 0.155mmol, 42% conditions E). The product was 
obtained as mixture of E/Z isomers:  
1H NMR (500 MHz) (CDCl3) δ 7.34 (d, 1H, J=8.9Hz, Cys (NH)), 6.88 (d, 1H, J=8.88 
Hz, Val (NH)) 6.84 (d, 1H, J=9.1Hz, Val (NH)), 5.70 (ddd, 1H, J=5.7Hz, J=12.8Hz, 
J=17.5Hz, Glu (CH=CH2)), 5.61 (ddd, 1H, J=5.6Hz, J=8.8Hz, J=14.7Hz, Cys 
(CH=CH2)), 5.53 (d, 1H, J=8.2Hz Glu (NH)), 4.74 (m, 1H, OCH2), 4.57 (m, 1H, Cys 
α CH), 4.39 (m, 2H, Val α CH and Glu α CH), 4.29 (m, 1H, OCH2), 3.78 (s, 3H, 
OCH3), 3.25 (dd, 1H, J=9.0Hz, J=13.9Hz, SCH), 3.07 (ddd, 2H, J=5.5Hz, J=14.2Hz, 
J=19.6Hz, SCH), 2.66 (ddd, 1H, J=6.8Hz, J=13.7Hz, J=18.0Hz , CH2S), 2.45 (m, 2H, 
γ CH2), 2.23 (m, 1H, Val (CH), 1.98 (m, 2H β CH2), 1.45 (s, 9H, C(CH3)3), 0.96 (m, 
6H, Val C(CH3)2);  
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13C NMR (75 MHz) (CDCl3) δ 172.1, 171.5, 171.4, 170.4, 155.3, 130.4, 128.1, 79.8, 
64.0, 58.3, 53.2, 52.6, 51.4, 32.2, 31.3, 30.8, 30.0, 28.2, 27.7, 18.9, 18.1;  
LRMS [ES+ M + [H+] Calcd for C23H37N3O8S 516.5 found 516.3].  
 
Synthesis of 4-F-Ph-SO2-N-Tyr-Leu-Gly-ene-Macrocycle-OMe (4.6) 
 
H
N
O
SF
O
O NH
O
O
H
N O
O
E/Z 4.6
 
 
RCM 4-F-Ph-SO2-N-Tyr-O-Allyl-Leu-Gly-allyl-OMe 3.64 (2.95g, 4.9mmol) (1.18g, 
was achieved via general procedure F Rf = 0.3 (1/1 (EtOAc / (50/70) Pet ether)). 
Purification was achieved using flash chromatography eluting with a gradient of 
(50/70) Pet ether to 100 % EtOAc to yield a brown solid 4.6 (0.92g, 1.6mmol, 65% 
condition F).  The product was obtained as a mixture of E/Z isomers:  
1H NMR (500 MHz in DMSO) δ 8.18 (1H, d J=7.6Hz, Phe (NH)), 8.08 (1H, d 
J=8.3Hz, Gly (NH)), 7.89 (2H, dd J=6.9Hz, J=13.6Hz, Ar-H (4-F-Ph)), 7.58 (1H, d 
J=7.5Hz, Leu (NH)), 7.34 (2H, t J=8.0Hz, Ar-H (4-F-Ph)), 6.90 (2H, d J=7.5Hz, Ar-
H (Tyr)), 6.64 (2H, d J=7.7Hz, Ar-H (Tyr)), 5.54 (1H, m, OCH2CHCH), 5.40 (1H, m, 
OCH2CHCH), 4.62 (2H, m, OCH2CHCH), 4.25 (2H, m, Tyr α CH) and Gly α CH), 
3.80 (m, Leu α CH), 3.54 (3H, s, CO2CH3), 2.65 (2H, m, Tyr (CH2)), 2.19 (2H, m, 
OCH2CHCHCH2), 1.19 (2H, m, CHCH2 Leu), 1.01 (1H, m, CHCH2 Leu), 0.70 (6H, 
m, Leu (CH3)2);  
LRMS [ES+ M + [H+] Calcd for C28H34FN3O7S 575.6 found 575.7].  
.  
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Synthesis of N-Cbz-Gln-Val-Gly–ene-Macrocycle-OMe (2.4) 
 
O
H
N
O
N
H
N
H
O
O H
N
O
O
O
E/Z 2.4
 
 
RCM 4-F-Ph-SO2-N-Tyr-O-Allyl-Leu-Gly-allyl-OMe 3.52 (0.79, 1.3mmol) and was 
achieved via general procedure F. The crude compound was sonicated in methanol 
solvent for 10min and the resulting solid was collected via Buchner funnel (Pyrex 5) 
to gave grey compound 2.4   (0.09g, 0.18mmol, 14%).  The product was obtained as a 
mixture of E/Z isomers:  
1H NMR (500 MHz) (DMSO) δ 8.32 (d, 1H, J=8.5Hz, Gly (NH)), 8.12 (d, 1H, 
J=9.0Hz, Glu (NH)), 7.75 (d, 1H, J=9.4Hz, Val (NH)), 7.55 (dd, 1H, J=4.7Hz, 
J=6.4Hz, CONHCH2), 7.28 (m, 5H, Cbz), 5.47 (m, 1H, Gln (CH=CH2)),  5.28 (m, 
1H, Gly (CH=CH2)), 4.99 (d, 2H, J=10.7Hz, OCH2), 4.4 (m, 1H, Gly α CH),  4.32 
(m, 1H, Gly α CH), 4.21 (m, 1H, Val α CH), 4.06 (m, 1H, Glu α CH), 3.81 (m, 1H, 
CONHCH2), 3.60 (s, 3H, OCH3), 3.23 (m, 1H, CONHCH2), 2.18-2.35 (m, 4H, Gly 
CH2, Gln γ CH2), 1.7-1.9 (m, 3H, Val (CH), Gln β CH2), 0.96 (m, 6H, Val C(CH3)2);  
13C NMR (75 MHz) (DMSO) δ 171.7, 171.5, 171.0, 170.6, 155.7, 137.1, 131.0, 
129.6, 128.4, 127.8, 124.8, 65.4, 58.1, 53.2, 52.0, 51.0, 41.5, 32.5, 30.9, 29.9, 27.2, 
18.9, 18.6;  
LRMS [ES+ M + [H+] Calcd for C25H36N4O7 503.5 found 503.4].  
 
 
 
 
 
 
 
 
Chapter 6 - Experimental  
_____________________________________________________________________ 
125 
 
6.4  REFERENCES FOR CHAPTER 6: 
 
(1) Armarego, W. L., Chai, L.L.C. Purification of Laboratory Chemicals; 5th ed.; 
Butterworth-Heinemann: Cornwall, 2003. 
(2) Xia, Z.; Smith, C. D. J.Org.Chem 2001, 66, 5241-5244. 
(3) Webster. K, L.; Maude. A, B.; M.E;, O. D.; Mehrotra. A, P.; D, G. 
J.Chem.Soc.,Perkin Trans 2001, 1, 1673-1695. 
 
